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Chapter 1. General introduction
Heart failure (HF) is a progressive disease for which comprehensive, long-term dis-
ease management is needed [1]. It is one of the major causes of morbidity and mor-
tality in the developed countries, with a prevalence of 2-3% [2] and death rates of
20-40% within 1-year and up to 70% in 5 years of diagnosis [3]. It is a complex con-
dition that can be caused by different reasons and it is often co-existing with other
comorbidities. One common cause of HF is coronary artery disease, but many other
factors including hypertension, obesity, diabetes, arrhythmias, heart valve disease can
lead to HF [2, 4, 5, 6]. Managing HF is difficult because besides medical treatment it
requires significant lifestyle changes such as exercise, restricted fluid and salt intake
and medication adherence. Despite the improvements in disease management, HF pa-
tients need to learn how to live with the medication and daily limitations in mobility
and nutrition. Therefore, HF is often associated with poor quality of life and multiple
hospital admissions.
About 23 million adults worldwide have been diagnosed with HF [2], while one per-
son in five is expected to develop HF at some point in their life, in economically devel-
oped countries [7]. 1–3% of all hospital admissions in Europe and the USA are related
to HF, while HF is the most common cause of hospitalization in patients over 65 years
[3]. In developed countries HF related costs are reflecting approximately 1–2% of all
health-care expenditures [8]. Approximately 227,000 people with heart failure are liv-
ing in the Netherlands [9] and 900,000 people in the UK. In the UK, HF patients are
consuming up to 2% of total NHS expenditure [10]. High healthcare cost expenditures
have been also reported for the US population [11], where over $30 billion is spent for
HF patients annually [2, 12].
One way to reduce cost and disease burden is by keeping patients out of hospital.
Approximately 25% of the HF patients are re-admitted within 30 days of discharge
from the hospital [3]. These re-admissions may be partially caused by worsening HF
or other cardiovascular reasons. However, other factors may contribute, such as co-
morbidity, frailty, poor cognition or social support or poor discharge services at hospi-
tal. Recurrent admissions represent a substantial impairment in a patient’s quality of
life and are associated with high costs and increased mortality [13].
Not all re-admissions are preventable, since they might be related to unavoidable pro-
gression of the disease [14, 15]. However, identifying and preventing re-admissions
that can be avoided is a great benefit to both patients and the health care system. A
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portion of re-admissions can be prevented by predicting if they will occur and tailor-
ing disease management interventions accordingly.
TABLE 1.1: Heart failure statistics
Prevalence worldwide 23 million
Prevalence in USA 6.5 million [12]
Prevalence in UK 900,000
Prevalence in the Netherlands 227,000
HF hospital admissions 1–3% of total admissions in Europe and USA
30day re-admission rate 25%
1-year death rate 20-40%
5-year death rate up to 70%
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PREDICTION MODELS IN HF
Outcomes, validation and generalizability
Many studies have been conducted aiming to predict adverse events in HF patients
in order to identify risk factors of these events and optimize the care provided to the
patients and their quality of life. In a systematic review, Rahimi et al. (2014) reported
64 risk prediction models for HF patients: 43 for death, 10 for re-admission and 11
predicting both (composite outcome) [16]. The discriminatory ability of the models
was significantly higher for prediction of death compared to the models predicting re-
admission or the composite outcome. Conclusion of this study was that there are clin-
ically useful and well-validated death prediction models available but re-admission
or composite outcome models are mainly performing poorly. Other earlier systematic
reviews also reported poor discriminative ability for re-admission and concluded that
predicting re-admission is challenging [17, 18].
Overall, the similarities of the reported studies suggest potential generalizability and
wider clinical use of a model, however models have been hardly tested in a different
setting [16]. Validation of the models in an external population and calibration (agree-
ment between prediction and observed outcomes) have been overlooked [19].
Methodology
In the development of these models, regression techniques were most often used. At-
tempts to improve the discriminative power of re-admission models by using more
advanced machine learning techniques did not show any improvement implying that
the poor performance is not related to methodological issues but possibly can be ex-
plained by other significant predictors that are still unknown to us [20]. Another ad-
vantage of regression models compared to machine learning techniques is that they
are easily interpretable by the clinical audience and that they allow for validation and
can be updated by simple adjustments to local settings [21].
Predictors
Rahimi et al. (2014) reported a list of the most often considered predictors. Variables
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often appearing in the models predicting death were age, renal function, blood pres-
sure, sodium level, ejection fraction, sex, NT-proBNP, New York Heart Association
class, diabetes, weight/body mass index (BMI) and exercise capacity [16]. In mod-
els predicting re-admission age, sex, renal function, cardiovascular disease, and heart
rate were the most common variables while renal function, NT-proBNP, history of HF,
age and blood pressure were the most common variables in the composite outcome
models [16]. Increasing age and renal dysfunction were the predictors overlapping
in all three cases [Table 1.2]. Most of the identified predictors were related to demo-
graphic, HF or other clinical conditions, while other risk factors that may affect the
outcomes, such as frailty [22], depression [23], poor cognition [24] or social factors [23]
were overlooked.
TABLE 1.2: Common predictors of outcomes in HF patients [16]
Outcome Predictors
Mortality Age, sex, renal function, blood pressure, sodium level,
ejection fraction, NT-proBNP, New York Heart Association class,
diabetes, weight/body mass index (BMI), exercise capacity
Re-admission Age, sex, renal function, cardiovascular disease, heart rate
Re-admission or morality Age, renal function, NT-proBNP, history of HF, blood pressure
6
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METHODOLOGY
We designed the OPERA-HF study, in the UK, to explore a wide range of variables
that were not taken into account in previous research. In particular, we explored non-
disease specific or non-clinical variables that could act as predictors for re-admission
or mortality in patients with HF following an admission for HF. We aimed to identify
variables that could improve the discrimination for re-admission or mortality predic-
tion. In order to validate our findings and their generalizability beyond the devel-
opment cohort we utilized the SAPHIRE study, a patient cohort from the US [Table
1.3].
TABLE 1.3: Study characteristics; patients eligible for our analysis: heart failure, sur-
vived discharge with available follow-up data
OPERA-HF SAPHIRE-HF/COPD
(N = 1094) (N = 513)
Study design Observational cohort Observational cohort
Geographical location Hull, UK St. Louis, Missouri, US
Time window Oct. 2012 − Nov. 2016 Oct. 2014 − Jan. 2017
30 day unplanned re-admission, n (%) 213 (19%) 72 (14%)
30-day mortality, n (%) 60 (5%) 27 (5%)
Age (years), median [IQR] 77 [68 − 83] 73 [62 − 82]
Women, n (%) 433 (40%) 265 (52%)
Length of stay (days), median [IQR] 10.1 [6.0 − 17.0] 4.8 [3.1 − 7.7]
OPERA-HF
The OPERA-HF is a prospective observational study enrolling patients hospitalized
for HF in the Hull & East Yorkshire Hospitals NHS Trust, UK. The aim of the study
is to create a holistic view of the patients, their general condition and co-morbidities,
and to identify predictors of mortality and re-admission to hospital. The study started
in October 2014 and we take into account data of patients enrolled till November 2016.
Clinical and non-clinical data were collected during hospital admission and just prior
7
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to discharge. Psychosocial information including depression and anxiety, cognitive
function and social support was collected during hospitalization through question-
naires that the patient was asked to complete. Additional assessments including frailty
assessment were also performed during hospitalization.
Patients had to fulfill the following criteria to be included in the present study: age
> 18 years; usual residence in the region served by the Hull & East Yorkshire Hospi-
tals Trust; hospitalization for HF; treatment with loop diuretics; and at least one of the
following: left ventricular ejection fraction (LVEF) ≤ 40%, left atrial dimension > 4.0
cm [25] or NT-ProBNP > 400 pg/ml (if in sinus rhythm) or > 1200 pg/ml (if in atrial
fibrillation) [26]. Patients who were unable to understand and comply with the pro-
tocol or unable or unwilling to give informed consent were not included in the study.
The study has ethical approval from the South Yorkshire Research Ethics Committee
(REC ref: 12/YH/0344) and is conducted in accordance with ICH-GCP, Declaration of
Helsinki, the Data Protection Act 1998 and the NHS Act 2006.
SAPHIRE-HF/COPD
The observational study on clinical data to assess and predict the clinical, financial,
and behavioral risk of re-admission or mortality of patients hospitalized for HF and
COPD (SAPHIRE-HF/COPD) is a prospective cohort study consisting of patients aged
18 years and older who were admitted to Mercy Hospital in St. Louis, Missouri for HF
and/or COPD. The study started in October 2014 and ended in January 2017. The aim
of the study is to identify contributing factors to adverse outcomes for HF and COPD
patients, to evaluate the added value of non-clinical factors and to analyze the validity
and predictability of prediction models beyond a single disease population. All partic-
ipants had to provide written informed consent and meet all of the following inclusion
criteria: physically and mentally capable to cooperate based on clinical judgement of
the care manager nurse, understand and speak the English language and willing to
fill out the questionnaires during their hospitalization. Patients were excluded for any
of the following reasons: only admitted to observation unit, part of another research
study involving novel medications or devices, illicit drug use, or designated for trans-
port to hospice at discharge. The study was approved by Mercy Health’s Institutional
Review Board.
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AIMS AND OUTLINE OF THIS THESIS
The main aim of this thesis is to explore risk factors associated to an increased risk
of adverse outcomes for HF patients and improve the early re-admission or mortal-
ity prediction in HF. In the first part of this thesis we study psychosocial factors. We
explore the impact of depression or anxiety on mortality in HF patients by means of
a systematic review of existing scientific literature. We then estimate the impact of
depression on mortality in the OPERA-HF study. We extend our scope beyond de-
pression or anxiety, by taking into account living status, cognitive impairment and
frailty and we study the impact of these risk factors on the combined outcome of re-
curring re-admissions or mortality. In the second part of this thesis we use prediction
model methods to develop and externally validate a risk prediction model for early
re-admission or mortality taking into account new predictors. The aim of this thesis is
reflected in the following research questions.
• What is the impact of depression and anxiety on mortality in HF patients?
• Which other psychosocial factors affect adverse outcomes in HF? What is their
association with first and recurrent events?
• Can we predict early re-admission or mortality with a model that is transportable
to a different geography?
This thesis consists of four parts. Part I (Chapter 1) includes the general introduction
and the research questions. Part II (Chapter 2, 3 and 4) is addressing the first and sec-
ond research questions. The third research question is approached in Part III (Chapter
5 and 6) where we report results on development and external validation of an early
outcome risk model. These parts are followed by Part IV (Chapter 7), which includes
the general discussion, summarizes the main findings of this thesis and provides an-
swers to the aforementioned research questions and recommendations for future re-
search.
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2 Depression and anxiety as predictors
of mortality among HF patients:
systematic review and meta-analysis
This article was published as “I. Sokoreli, J. J. G. de Vries, S. C. Pauws, and E. W. Steyerberg, ”De-
pression and anxiety as predictors of mortality among heart failure patients: systematic review and
meta-analysis”, Heart failure reviews, vol.21, no.1, pp.49-63, 2016.”
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Chapter 2. Depression and anxiety as predictors of mortality
ABSTRACT
Aims: Several studies suggest that psychological factors are associated with negative
outcomes and in particular higher mortality rates among Heart Failure (HF) patients.
We aimed to evaluate the effect sizes of depression and anxiety on all-cause mortality
in HF patients.
Methods and results: We conducted a systematic review according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology.
We searched for studies on depression or anxiety effects on all-cause mortality among
HF patients published up to June 2015. A number of 26 and 6 articles met inclusion
criteria for depression (total 80627 patients) and anxiety (total 17214 patients) respec-
tively. The effect estimates were pooled using random-effect meta-analysis.
Depression has significant and moderately heterogeneous effect on all-cause mortality
(HR = 1.57; 95%CI 1.30 – 1.89, P < 0.001); adjustment for confounders led to a similar
effect estimate (HR = 1.40; 95%CI 1.22 – 1.60; p < 0.001). Larger studies and higher
study prevalence of depression were associated with smaller effect size. The effect of
anxiety on mortality outcome was small and not conclusive given the low number of
studies (n=6) (HR = 1.02; 95% CI 1.00 – 1.04, P < 0.05).
Conclusions: This systematic review and meta-analysis suggests that depression is an
important and independent predictor of all-cause mortality among HF patients, while
anxiety does not appear to have a strong effect. Further research is recommended
towards the detection and treatment of depression.
17
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INTRODUCTION
Heart Failure (HF) is defined as a clinical syndrome in which patients have typical
symptoms such as breathlessness, ankle swelling, and fatigue and signs such as ele-
vated jugular venous pressure, pulmonary crackles, and displaced apex beat, resulting
from an abnormality of cardiac structure or function [1]. Approximately 1–2% of the
adult population in developed countries has HF, with the prevalence rising to ≥ 10%
among persons 70 years of age or older [2]. HF is one of the most common causes of
hospital readmission and mortality.
Psychological factors such as depression or anxiety are often reported with high preva-
lence and strong association with negative outcomes in patients with cardiovascular
disease [3]. Many studies have reported high rates of depression among HF patients.
A prior systematic review and meta-analysis published by Rutledge in 2006 [4] re-
ported an overall aggregated depression prevalence rate of 21.6% among HF patients,
while individual study prevalence estimates ranged from 9% to 60%. Moreover, in
2005 Konstam [5] reported that approximately 40% of HF patients may suffer from
major anxiety, and overall anxiety levels are 60% higher than levels seen in the healthy
population.
Depression has been linked to increased risk of negative outcomes, such as rehospi-
talization and mortality among HF patients. According to a previous meta-analysis,
the aggregated risk estimate derived from 8 studies suggested a greater than 2-fold
risk of death and secondary events for HF patients with heightened depressive symp-
toms or a depressive disorder [4]. A similar analysis was also published by Fan [6] in
2014 on 9 prospective studies, who reported a pooled Hazard Ratio of 1.51 for patients
with depression compared to patients without depression. In both cases the result
was strongly heterogeneous but no further analysis, such as meta-regression, was per-
formed to examine the sources of this heterogeneity. On the other hand, there is, to the
best of our knowledge, no meta-analysis published about the prevalence of anxiety
among HF patients and the effect of anxiety on mortality outcome. Even though anx-
iety is usually correlated with depression, it has not extensively been studied among
patients with HF.
Our aim is to provide an updated systematic review of prospective or retrospective
studies and a meta-analysis of the effect of depression and the effect of anxiety on
18
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mortality among HF patients. To reach this objective, we searched extensively for
available studies investigating the impact of depression and anxiety on mortality of
HF patients. Within these studies, we identified also the reported prevalence of de-
pression or anxiety among HF patients.
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METHODS
Search strategy and selection criteria
This systematic review and meta-analysis were conducted according to the guidelines
introduced in the Preferred Reporting Items for Systematic reviews and Meta-analysis
(the PRISMA Statement) [7]. The 27 checklist items of the PRISMA methodology fol-
lowed are given in Appendix A. Three electronic databases (MEDLINE, BIOSIS and
EMBASE) were searched for studies that investigated the relationship between depres-
sion or anxiety and mortality among Heart Failure (HF) patients. No publication time
restriction was applied. All papers written in English and published before the 25th of
June 2015 were included. Selected journals as well as the references of full-text papers
were also hand-searched, when necessary, in order to identify studies that meet the
inclusion criteria.
The database search string was created according to the PICO model (P, population/
patient; I, intervention/indicator; C, comparator/control; and O, outcome). For the
“P” in PICO the “HEART FAILURE” keyword was included. For the “I”, the following
keywords: “DEPRESS? OR STRESS OR ANXIETY OR PSYCHOLOG?”. For the “C”,
no particular terms were used in our case. For “O”, we used the following keywords:
“MORTALITY OR DEATH”. The complete query as used for the databases search is
given in Appendix B.
Study selection
In our analysis, several inclusion and exclusion criteria were defined. All studies that
met those criteria were included. The inclusion criteria were articles presenting stud-
ies focusing on the association between depression or anxiety and mortality in a HF
adult population. All mortality outcomes such as all-cause or cardiac related mortality
were included and studies focusing on inpatient, outpatient or both care settings were
taken into account. On the other hand, publications analyzing data that had already
been used before for the same purpose, studies introducing no quantitative assess-
ment of the impact of depression or anxiety on the outcome or analyzing the use of
antidepressants as primary focus were excluded from our analysis.
20
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Review process and data collection
All titles and abstracts of studies identified by the electronic and hand search were
screened by the reviewer (IS) to identify those meeting the inclusion/ exclusion cri-
teria. Then, all the selected full texts were screened independently by two reviewers
(IS, GJdV) to identify which articles should be included in the systematic review. Any
disagreement between the reviewers was resolved by a third reviewer (SP). For each
of the selected articles the reviewers extracted data about author, year of publication,
follow-up period, outcome variable, location, study design, study population (size/
type), prevalence of depression or anxiety, assessment method of the psychological
parameter, other parameters, statistical method and results.
Mendeley 1.13.8 software was used for organizing and managing of the articles.
Data analysis
All studies were categorized according to the psychological factor investigated (de-
pression or anxiety). Information was extracted according to whether the analysis was
adjusted for confounders such as age, gender, and clinical severity. For both groups
the association between depression or anxiety and mortality was reported by collect-
ing information of the hazard ratios/odds ratios, 95%CI and/or p-values.
Random-effects meta-analysis was applied to combine the results. We decided to pool
not only the adjusted effect but also the unadjusted effects in order to avoid the bias
of the different adjustments. For the few cases where Odds Ratios were reported,
they were converted [8] into Hazard Ratios in order to be comparable with the other
Hazard Ratios. In studies where results were presented for several periods of follow-
up we selected the longest follow-up period to avoid bias of including multiple results
on the same patient data.
Studies collected in our analysis were different with respect to patient population, lo-
cations and depression or anxiety assessment methods. The random-effects method
allows for heterogeneity by assuming that the effects being estimated in the different
studies are not identical, but follow a normal distribution. Heterogeneity across the
studies was quantified by the I2 statistic [9]. The I2 statistic summarizes the fraction
of the variation across studies due to heterogeneity relative to chance. Random-effect
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meta-regression was used in an attempt to explain between-study heterogeneity and
identify possible sources of bias. Meta-regression is a method to quantify the associa-
tion between the estimated effect of depression and different study characteristics.
Meta analyses were presented in the form of forest plots created with the metafor pack-
age for R statistics version 3.0.3 (The R Foundation for Statistical Computing).
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RESULTS
Search result
A total of 906 potentially relevant articles was identified from the electronic search
and 5 from the hand search. After removing the duplicates and reviewing the titles
and abstracts we ended up with 62 articles for a full text review. From these, 35 more
articles were excluded, leaving 27 articles for the systematic review (Figure 2.1).
Characteristics of the selected studies
Depression and mortality
Among the identified studies, 26 reported on the effect of depression. The prevalence
of depression varied from 10 to 79% in the identified literature studies. The unad-
justed effect of depression is presented in Table 2.1, while the effect of depression after
adjusting for several confounders in Table 2.2. The most common confounders, used
in more than 10 studies, were age, gender, NYHA class and (left ventricular) ejection
fraction. There were various techniques used among the studies to assess depression
levels. We included all studies assessing for clinically significant depression. The most
common scale used was the Beck Depression Inventory (BDI) [10], followed by the Pa-
tient Health Questionnaire (PHQ) [11].
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TABLE 2.1: Unadjusted effect of depression on all-cause mortality among HF patients
Author Year Assessment
method
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HR, hazard ratio; OR, odds ratio; CI, confidence interval; BDI, Beck depression inventory; GDS, geriatric depression scale; PHQ, patient health questionnaire;
ICD, international classification of diseases; HADS-D, hospital anxiety and depression scale - depression; CES-D, center for epidemiological studies depression;
HDRS, Hamilton rating scale for depression; SCL-20, Hopkins symptom checklist- 20-item depression scale; PRIME-MD, primary care evaluation of mental disorders;













TABLE 2.2: Adjusted effect of depression on all-cause mortality among HF patients
Author Year Assessment
method
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1.4 <0 .01 1.05−
1.86
24%
HR, hazard ratio; OR, odds ratio; CI, confidence interval; BDI, Beck depression inventory; PHQ, patient health questionnaire; CES-D, center for epidemiological studies
depression; ICD, international classification of diseases; GDS, geriatric depression scale; HADS-D, hospital anxiety and depression scale - depression; HDRS, Hamilton rating
scale for depression; SCL-20, Hopkins symptom checklist- 20-item depression scale; PRIME-MD, primary care evaluation of mental disorders; PFOS, psychosocial factors
outcome study; NYHA, New York heart association; CABG, coronary artery mypass grafting; ACE, angiotensin converting enzyme; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HR, heart rate; BNP, b-type natriuretic peptide; LVEF, left ventricular ejection fraction; DM, diabetes mellitus; COPD, chronic obstructive pulmonary
disease; CrC, creatinine clearance by Cockcroft formula; BMI, body mass index; ARB, angiotensin receptor blocker; BB, beta-blockers; CHD, coronary heart disease;
CCI, Charlson comorbidity index
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The pooled hazard ratio for the unadjusted effect of depression on mortality was
strongly significant across 15 studies (HR = 1.57; 95%CI 1.30 – 1.89; p < 0.001). The
pooled estimation was strongly heterogeneous as reflected by the I2 statistic (I2 = 94%,
heterogeneity p < 0.001). The pooled adjusted Hazard Ratio was also significant (HR
= 1.40; 95%CI 1.22 – 1.60; p < 0.001) and again heterogeneous (heterogeneity p < 0.001;
I2 = 97%, Figure 2.2).
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FIGURE 2.2: Meta-analysis – Forest plot calculating the effect of depression (a) unad-
justed effect, (b) adjusted effect
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A random-effect meta-regression was performed to understand the sources of the
higher than 90% observed heterogeneity between the studies. The potential study-
level covariates analyzed were the study characteristics introduced in Tables 2.1, 2.2.
There was no association found between heterogeneity and the depression assessment
method, the adjusted or univariate analysis, the location where the study was con-
ducted, the inpatient or outpatient predictive period, the year of the study, the type of
the study and the follow-up period. On the other hand, significant heterogeneity was
associated with the total population size (smaller effect in larger studies p < 0.01) and
the prevalence of the depression in the study (smaller effect for prevalence >29%; p <
0.01, Table 2.3).
Anxiety and mortality
Only 6 studies analyzing the effect of anxiety on mortality among HF patients were
identified with a prevalence of anxiety varying from 9 to 53%. Table 2.4 shows the
unadjusted effects reported in the studies and Table 2.5 the reported effects on mortal-
ity after adjusting for a group of confounders. Age, NYHA class and (left ventricular)
ejection fraction were the most common confounders in the identified studies.
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TABLE 2.3: Random-effect meta-regression; Univariate Analysis
Estimated coefficient (SE) p-value
Year -0.0016 (0.0124) 0.8957
Assessment method
BDI 0.0349 (0.1287) 0.7863
PHQ 0.2096 (0.1433) 0.1434
Other -0.1571 (0.1117) 0.1596
Population size -0.0004 (0.0002) <0.05
Region
EU -0.1119 (0.1134) 0.3241
US 0.04355 (0.1140) 0.7555
Follow-up period 0.0014 (0.0269) 0.9599
Statistical method
Unadjusted 0.1066 (0.1159) 0.3573
Adjusted Reference Reference
Study type
Prospective 0.1453 (0.1134) 0.2003
Retrospective 0.0667 (0.2217) 0.7637
Other -0.1756 (0.1178) 0.1359
Depression prevalence -0.0108 (0.0059) <0.1
Predicting period
Inpatient -0.1641 (0.1156) 0.1156
Outpatient Reference Reference
In order to estimate the unadjusted effect of each study-level factor, the studies with missing













TABLE 2.4: Unadjusted effect of anxiety on all-cause mortality among HF patients
Author Year Assessment
method
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TABLE 2.5: Adjusted effect of anxiety on all-cause mortality among HF patients
Author Year Assessment
method
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HR, hazard ratio; OR, odds ratio; CI, confidence interval; BSI, Brief symptom inventory; ICD, international classification of diseases; STAI, State-Trait anxiety inventor;
HRQL, health related quality of life; HADS-A, hospital anxiety and depression scale - anxiety; PFOS, psychosocial factors outcome study; NYHA, New York heart association;
BDI, Beck depression inventory; LVEF, left ventricular ejection fraction; EF, ejection fraction
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There was no evidence found for anxiety as an independent predictor of mortality.
The pooled hazard ratio for the unadjusted effect of anxiety on mortality, which was
based on 2 studies, was 1.02 (95% CI 1.00 – 1.04; p = 0.24, heterogeneity p = 0.38; I2
= 0%). The pooled hazard ratio for the adjusted effect of anxiety on mortality could
be based on 5 studies and was identical (HR = 1.02; 95% CI 1.00 – 1.04; p = 0.09) and
reasonably homogenous (heterogeneity p = 0.97; I2 = 0%, Figure 2.3)).
FIGURE 2.3: Meta-analysis – Forest plot calculating the effect of anxiety (a) unadjusted
effect, (b) adjusted effect
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DISCUSSION
This systematic review was conducted according to the PRISMA guidelines to assess
the evidence on the effect of depression (26 studies) and anxiety (6 studies) on all-
cause mortality outcome among Heart Failure (HF) patients. <Key results: 1.6 for
depression but very heterogeneous across studies; no effect for anxiety>. In contrast
to other reviews, our study was not limited on follow-up duration or only in prospec-
tive studies reporting adjusted effects of the two parameters. We reviewed all studies
published quantifying the effect of depression or anxiety.
The prevalence of depression varied among the 26 different studies with an average
of approximately 29% ranging from 10 to 79%. The meta-analysis showed that the
unadjusted risk of death among HF patients facing depression was 1.57 times higher
than the risk among HF patients without depression and the pooled estimate of the
adjusted Hazard Ratio was 1.40. In both univatiate and adjusted analysis, strong het-
erogeneity among the studies was found. Our findings are more conservative than
previous reviews published [4, 6]. Rutledge et al reported a 2.10 higher adjusted risk
of mortality and secondary events based on 8 studies and Fun et al reported a pooled
adjusted Hazard Ratio of 1.51 based on 9 studies, both with substantial heterogeneity.
From our attempt to explain heterogeneity we found that the effect of depression is
weaker in larger studies; this suggests publication bias: small studies were published
if they found relatively large effect estimates, while small studies with modest effect
estimates were not. The weaker effect in studies with higher prevalence of depression
may relate to the use of different cut-offs on an underlying, latent, scale for depression.
If a more liberal cut-off was used, those labeled as depressed actually were milder than
with a more strict definition of depression.
Our results for anxiety do not have the same weight as the results with respect to de-
pression since anxiety was less studied in the literature. Anxiety had a similar preva-
lence to depression among the six identified studies (average 29%, range 9− 45%), but
patients with anxiety had no increased risk of death compared to those without anxi-
ety. However, since anxiety is usually correlated with other factors such as depression,
further research of anxiety as a covariate to other factors is recommended.
One limitation of our study is related to the variation in follow-up times. Follow-up
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times varied from 30 days to a number of years; furthermore, there were studies cov-
ering different follow-up periods but in these cases we always selected the longest
follow-up. Further analysis such as subgroup analysis would be recommended to
investigate the effect variation in different follow-up periods, however limited infor-
mation in some of the literature publications is restrictive towards this direction.
Moreover, we focused only on mortality. Nevertheless, there is evidence that depres-
sion and anxiety are also associated to other adverse events such as readmission. Fur-
ther investigation in needed also towards this direction. One limitation of the meta-
regression is that even though we tried to cover a broad selection of study-level covari-
ates there are more that might also be related to the heterogeneity. Further research on
different factors’ interactions would be recommended.
The ”gold standard” test of causality of a putative risk factor is a randomized clinical
trial. Such a trial minimizes concerns about confounders [39, 40, 41]. To the best of
our knowledge, there is no randomized clinical trial conducted for depression among
a HF population. Based on our findings we strongly recommend such a trial in order
to evaluate the causality of depression.
Finally, according to our findings from the meta-regression, depression should not be
underestimated in clinical practice within HF population groups where prevalence is
low. Furthermore, based on our overall findings on the effect of depression, we rec-
ommend further research on the recognition and management of depression in clinical
practice which might improve patient outcomes. Further analysis such as subgroup
analysis and interventional studies are required for stronger evidence towards this
direction.
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APPENDIX A: PRISMA CHECKLIST
TABLE 2.6: PRISMA checklist
Section/ topic N Checklist item Page
TITLE
Title 1 Identify the report as a systematic review, meta-analysis, or both. 15
ABSTRACT
Structured summary 2 Provide a structured summary including, as applicable: background; ob-
jectives; data sources; study eligibility criteria, participants, and interven-
tions; study appraisal and synthesis methods; results; limitations; con-




Rationale 3 Describe the rationale for the review in the context of what is already
known.
18-19
Objectives 4 Provide an explicit statement of questions being addressed with reference






5 Indicate if a review protocol exists, if and where it can be accessed (e.g.,
Web address), and, if available, provide registration information includ-
ing registration number.
Appendix A
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report
characteristics (e.g., years considered, language, publication status) used
as criteria for eligibility, giving rationale.
20
Information sources 7 Describe all information sources (e.g., databases with dates of coverage,
contact with study authors to identify additional studies) in the search
and date last searched.
20
Search 8 Present full electronic search strategy for at least one database, including
any limits used, such that it could be repeated.
Appendix B
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included




10 Describe method of data extraction from reports (e.g., piloted forms, in-
dependently, in duplicate) and any processes for obtaining and confirm-
ing data from investigators.
21
Data items 11 List and define all variables for which data were sought (e.g., PICOS,
funding sources) and any assumptions and simplifications made.
20-22
Risk of bias in indi-
vidual studies
12 Describe methods used for assessing risk of bias of individual studies
(including specification of whether this was done at the study or outcome
level), and how this information is to be used in any data synthesis.
21
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in
means).
21
Synthesis of results 14 Describe the methods of handling data and combining results of stud-
ies, if done, including measures of consistency (e.g., I2) for each meta-
analysis.
21
Continued on next page
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Table 2.6 – Continued from previous page
Section/ topic N Checklist item Page
Risk of bias across
studies
15 Specify any assessment of risk of bias that may affect the cumulative evi-
dence (e.g., publication bias, selective reporting within studies).
21
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup
analyses, meta-regression), if done, indicating which were pre-specified.
21
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included
in the review, with reasons for exclusions at each stage, ideally with a
flow diagram.
Fig. 2.1
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g.,




Risk of bias within
studies
19 Present data on risk of bias of each study and, if available, any outcome




20 For all outcomes considered (benefits or harms), present, for each study:
(a) simple summary data for each intervention group (b) effect estimates
and confidence intervals, ideally with a forest plot.
Tables
2.1,2.2,2.4,2.5;
Fig. 2.2 - 2.3
Synthesis of results 21 Present results of each meta-analysis done, including confidence inter-
vals and measures of consistency.
Fig. 2.2 - 2.3
Risk of bias across
studies
22 Present results of any assessment of risk of bias across studies (see Item
15).
34/ Table 2.3
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup
analyses, meta-regression [see Item 16]).
34/ Table 2.3
DISCUSSION
Summary of evidence 24 Summarize the main findings including the strength of evidence for each
main outcome; consider their relevance to key groups (e.g., healthcare
providers, users, and policy makers).
40-41
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at
review-level (e.g., incomplete retrieval of identified research, reporting
bias).
40-41
Conclusions 26 Provide a general interpretation of the results in the context of other evi-
dence, and implications for future research.
40-41
FUNDING
Funding 27 Describe sources of funding for the systematic review and other support
(e.g., supply of data); role of funders for the systematic review.
/
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APPENDIX B: DATABASE SEARCH QUERY
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Chapter 3. Prognostic value of depression in OPERA-HF
ABSTRACT
Background: Depression is associated with increased mortality among patients with
chronic heart failure (HF). Whether depression is an independent predictor of outcome
in patients admitted for worsening of HF is unclear.
Methods and results: OPERA-HF is an observational study enrolling patients hos-
pitalized with worsening HF. Depression was assessed by the Hospital Anxiety and
Depression Scale (HADS-D) questionnaire. Comorbidity was assessed by the Charl-
son Comorbidity Index (CCI). Kaplan-Meier and Cox regression analyses were used
to estimate the association between depression and all-cause mortality.
Of 242 patients who completed the HADS-D questionnaire, 153, 54 and 35 patients
had no (score 0−7), mild (score 8−10) or moderate-to-severe (score 11−21) depres-
sion, respectively. During follow-up, 35 patients died, with a median time follow-up
of 360 days amongst survivors (interquartile range, IQR 217 − 574 days). In univari-
able analysis, moderate-to-severe depression was associated with an increased risk of
death (HR: 4.9; 95% CI: 2.3 to 10.2; P < 0.001) compared to no depression. Moderate-
to-severe depression also predicted all-cause mortality after controlling for age, CCI
score, NYHA class IV, NT-proBNP and treatment with mineralocorticoid receptor an-
tagonist, beta-blocker and diuretics (HR: 3.0; 95% CI: 1.3 to 7.0; P < 0.05).
Conclusions: Depression is strongly associated with an adverse outcome in the year
following discharge after an admission to hospital for worsening HF. The association
is only partly explained by the severity of HF or comorbidity. Further research is
required to demonstrate whether recognition and treatment of depression improves
patient outcomes.
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INTRODUCTION
Psychosocial illness, including depression, is common in people with cardiovascular
disease. Depression is particularly common in patients with heart failure (HF) [1].
Probably most patients with HF are depressed by their illness at some time but a meta-
analysis suggests that depression affects about a 20% of patients at any time [2].
For patients with HF, depression is associated with an increased rate of adverse out-
comes [2, 3], such as hospitalization and death. The aggregated risk-estimate derived
from 26 studies was an approximately 1.5−fold risk of death in patients with HF if
they had depression [3]. However, it can be difficult to disentangle whether depression
causes a worse outcome, or merely reflects worse HF or more severe co-morbidity. We
aimed to assess the prevalence and consequences of depression in patients admitted
to hospital for worsening HF. We analyzed a prospective patient cohort and controlled
for common covariates reflecting the severity of both the HF and any comorbidities.
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METHODS
Study design
OPERA-HF is an ongoing prospective observational study, enrolling patients hospi-
talized with worsening heart failure (HF) to the Hull & East Yorkshire Hospitals NHS
Trust, UK. The aim of the study is to gather a holistic view of the patients, their general
condition and co-morbidities, and to identify predictors of mortality and re-admission
to hospital. Clinical and psycho-social data were collected during hospital admission
and just prior to discharge. The Charlson comorbidity index (CCI) was used to assess
comorbidity (Appendix A).
Patients had to fulfill all of the following criteria to be included in the study: age >
18 years; hospitalization for worsening HF; treatment with loop diuretics; and at least
one of the following: left ventricular ejection fraction ≤ 40%, left atrial dimension >
4.0 cm or NT-ProBNP > 400 pg/ml (if in sinus rhythm) or > 1200 pg/ml (if in atrial
fibrillation). Patients unable to understand and comply with the protocol or unable
or unwilling to give informed consent were excluded from the study. The study has
full ethical approval from the South Yorkshire Research Ethics Committee (REC ref:
12/YH/0344) and is conducted in accordance with ICH-GCP, Declaration of Helsinki,
the Data Protection Act 1998 and the NHS Act 2006.
Depression assessment
Depression was assessed by the Hospital Anxiety and Depression Scale (HADS-D)
questionnaire [4] (Appendix B). The HADS-D focuses on questions about depression.
The response to each of the 7 questions is graded from 0 to 3, giving a total score
that ranges between 0 and 21. A score of 7 or less implies that there is no depression; a
score of 8-10 suggests mild depression; and a score of 11 or higher reflects moderate-to-
severe depression [4]. Among 12 studies assessing the HADS-D questionnaire (total N
= 2109 patients), a cut point of 8 for the diagnosis of depression had a mean specificity
of 0.79 and a mean sensitivity of 0.83 when compared with a ‘gold standard’ diagnosis
using DSM-III/IV or similar codes [5].
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Mortality
All patients enrolled in the study are followed subsequent to discharge. Readmissions
and all-cause mortality are automatically recorded in the hospital’s IT system. For the
present report, the primary outcome of interest was all-cause mortality.
Statistical analysis
We report the baseline characteristics of the patients who participated in the study
between 14/10/2012 and 16/06/2015 and who completed the HADS-D questionnaire.
Follow up was censored at 13/07/2015. The consort diagram is given in Appendix C.
Univariable and multivariable Cox proportional hazard regression models were used
to estimate the association between depression and all-cause mortality. Univariable
analysis was performed to assess the relation between variables and outcome, includ-
ing demographics, clinical assessment, echocardiography and medication. In the mul-
tivariable model, we adjusted for all the variables found to predict outcome (P ≤ 0.1)
in the univariable analysis. Multiple imputation [6] was used to impute missing data
when needed. The Kaplan-Meier method was used to estimate survival time and pro-
duce a survival curve [7]. All analyses were conducted using R 3.1.3 statistical soft-
ware (The R Foundation for Statistical Computing, Vienna, Austria). In particular, the
R package mice [8] was used for the multiple imputation and the R package survival
[9] for the Kaplan-Meier method and the survival analysis.
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RESULTS
Baseline characteristics of the study population
The baseline characteristics of the 242 participants who completed the HADS-D ques-
tionnaire are reported in Table 3.1. The median follow-up was 315 days (interquartile
range, IQR 167 - 519) for all patients and 360 days (IQR = 217 - 574) amongst survivors.
The mortality rate estimated from the Kaplan Meier curve was 15% [95% CI 10% - 20%]
at one year.
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TABLE 3.1: Baseline characteristics stratified by HADS-D group and total population.
Characteristics are summarized by their count and fraction (N (%)) for categorical or
their median and interquartile range (Median [25th − 75th]) for continuous variables,
respectively; (∗) all variables are evaluated at admission apart from NT−proBNP and
LVEF which are evaluated at discharge and (∗∗) NYHA class which was evaluated as
the worst class during the last 7-days before admission (∗ ∗ ∗) Diuretics: loop diuretics
or thiazide
Depression Score All (N=242) 0 − 7 (N=153) 8-10 (N=54) 11-21 (N=35)
Characteristics (*) Valid N Summary Valid N Summary Valid N Summary Valid N Summary
Women, % 242 76 (31%) 153 48 (31%) 54 18 (33%) 35 10 (29%)
Age, years 242 74 [64−80] 153 73 [64−81] 54 74 [67−78] 35 73 [63−80]
CCI, score 221 3 [2 − 5] 143 3 [2 − 4] 46 3 [2 − 6] 32 3 [2 − 5]
NYHA**: Class I/II, % 209 32 (15%) 132 23 (18%) 48 7 (15%) 29 2 (6%)
NYHA: Class III, % 209 135(65%) 132 87 (66%) 48 32 (67%) 29 16 (55%)
NYHA: Class IV, % 209 42 (20%) 132 22 (17%) 48 9 (19%) 29 11 (38%)
Hypertension, % 235 130 (55%) 150 82 (55%) 53 27 (51%) 32 21 (66%)
NT-proBNP, pg/mL 204 4792[1694 130 5022[1782 45 3188[1323 29 5368[2830
− 9784] − 9668] − 9445] − 12290]
Heart Rhythm: Sinus, % 242 92 (38%) 153 50 (33%) 54 25 (46%) 35 17 (49%)
LVEF at discharge: ≤ 40% 216 128(59%) 142 89 (63%) 48 23 (48%) 26 16 (62%)
Main presentation:
- Severe peripheral oedema, % 236 24 (10%) 149 19 (13%) 52 3 (6%) 35 2 (6%)
- Severe breathlessness at rest, % 236 76 (32%) 149 56 (38%) 52 12 (23%) 35 8 (23%)
- Increasing exertional 236 106(45%) 149 53 (36%) 52 31 (60%) 35 22 (63%)
breathlessness, %
- Chest pain - cardiac, % 236 21 (9%) 149 14 (9%) 52 6 (11%) 35 1 (3%)
- Other symptom, % 236 9 (4%) 149 7 (5%) 52 0 (0%) 35 2 (6%)
HF Medication (on admission)
ACE inhibitor, % 242 98 (40%) 153 54 (35%) 54 24 (44%) 35 20 (57%)
ARB , % 242 48 (20%) 153 30 (20%) 54 12 (22%) 35 6 (17%)
Beta-blocker, % 242 126(52%) 153 70 (46%) 54 32 (59%) 35 24 (69%)
Aldosterone Antagonist,% 242 51 (21%) 153 29 (19%) 54 11 (20%) 35 11 (31%)
Digitalis, % 242 35 (14%) 153 19 (12%) 54 9 (17%) 35 7 (20%)
Diuretics ***, % 242 128(53%) 153 71 (46%) 54 30 (56%) 35 27 (77%)
NYHA, New York Heart Association; CCI, Charlson comorbidity index; LVEF, Left ventricular ejection fraction; SOB,
Acute shortness of breath;ACE, Angiotensin-converting enzyme; ARB: Angiotensin Receptor Blockers.
Depression assessment
The median HADS-D score amongst the 242 HF patients was 6 (IQR = 3 - 9); 153
patients had no (score 0-7), 54 had mild (score 8-10) and 35 had moderate-to-severe
(score 11-21) depression, respectively. Patients with moderate-to-severe depression
were, on average, in a worse NYHA class, had more likely sinus heart rhythm and
were taking more HF medications than those with no depression (Table 3.1).
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Patients were more likely to give high (i.e. worse) scores to the questions “I can laugh
and see the funny side of things” and ”I feel as if I am slowed down” (Table 3.2).
TABLE 3.2: Patients scoring of HADS-D questions; the score for each question ranges
from 0 (as the most positive response) to 3 (most negative response). The aggregated
scores are calculated based on the 242 HF patients answering the HADS-D question-
naire.
Question Score per answer Number of Aggregated score for 242
patients patients
I still enjoy the things Definitely as much - 0 58 294
I used to enjoy Not quite so much - 1 109
Only a little - 2 40
Hardly at all - 3 35
I can laugh and see As much as I always could - 0 1 623
the funny side of Not quite so much now - 1 18
things Definitely not so much now - 2 64
Not at all - 3 159
I feel cheerful Most of the time − 0 145 119
Sometimes - 1 79
Not often - 2 14
Not at all - 3 4
I feel as if I am slowed Not at all − 0 12 472
down Sometimes - 1 78
Very often - 2 62
Nearly all the time - 3 90
I have lost interest I take just as much − 0 117 194
in my appearance care as ever
I may not take quite 65
as much care - 1
I don’t take so much 51
care as I should - 2
Definitely - 3 9
I look forward with As much as ever I did - 0 94 224
enjoyment to things Rather less than I used to - 1 85
Definitely less than I used to - 2 50
Continued on next page
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Table 3.2 – Continued from previous page
Question Score per answer Number of Aggregated score for 242
patients patients
Hardly at all - 3 13
I can enjoy a good book Often − 0 155 126
or radio or TV program Sometimes - 1 59
Not often - 2 17
Very seldom - 3 11
Effect of depression on mortality
The unadjusted rate for all-cause mortality was almost five times higher amongst pa-
tients with moderate-to-severe depression compared to patients without depression
(HR: 4.9; 95% CI: 2.3 to 10.2; P < 0.001, Table 3.3a and Figures 3.1a). Increasing age (as
a continuous variable), increasing NT-proBNP (continuous), NYHA class IV within 7
days before admission (compared with patients with Class I/II), increasing CCI score,
and use of a mineralocorticoid receptor antagonist, beta-blocker and diuretic were all
associated with increasing mortality. We therefore corrected for these characteristics
in the multivariable analysis (Table 3.3b, Figure 3.1b). Moderate-to-severe depression
remained a significant predictor of all-cause mortality (HR: 3.0; 95% CI: 1.3 to 7.0; P <
0.05) along with NT-proBNP (HR: 1.7; 95% CI: 1.1 to 2.8; P < 0.05) and NYHA class
IV (HR: 1.2; 95% CI: 1.0 to 4.6; P < 0.1). Further details on the association between the
covariates and the outcome are provided in Table 3.4.
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TABLE 3.3: (a) Univariable analysis, (b) Multivariable analysis; (*) HR based on Cox
proportional hazard models; (**) adjusted for age (continuous), CCI score (continu-
ous), NYHA class IV (worst NYHA class during 7 days before admission - binary),
log(NT-proBNP) (continuous), Aldosterone Antagonist (binary), Beta-blocker (binary)
and diuretics (binary)
(a) Univariable analysis (N = 242 / events = 35) - Likelihood ratio test = 15.25 for 2 df, p<0.001
Depression status at admission HR for all-cause mortality* 95% CI p-value
None (reference) 1 − −
Mild 1.54 0.63 − 3.80 0.34
Moderate-to-severe 4.86 2.30 − 10.25 <0.001
(b) Multivariable analysis** (N = 242 / events = 35) - Likelihood ratio test = 41.5 for 9 df, p<0.001
Depression status at admission HR for all-cause mortality 95% CI p-value
None (reference) 1 − −
Mild 1.44 0.58 − 3.63 0.44
Moderate-to-severe 2.97 1.26 − 6.99 <0.05
HR, Hazard Ratio; CI, Confidence Interval.
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FIGURE 3.1: (a) Unadjusted cumulative incidence plot [analysis based on the imputed
dataset], (b) Cumulative incidence plot adjusted for age (continuous), CCI score (con-
tinuous), NYHA class IV (worst NYHA class during 7 days before admission - binary),
log(NT-proBNP) (continuous), Aldosterone Antagonist (binary), Beta-blocker (binary)
and diuretics (binary) [analysis based on the imputed dataset]
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TABLE 3.4: Univariable/Multivariable analysis
Univariable analysis Multivariable analysis
(N = 242 / events = 35) (N = 242 / events = 35)
HR 95% CI p-value HR 95% CI p-value
Women, yes 0.78 0.37 – 1.67 0.52 - - -
Age at admission (10 year increase) 1.68 1.17 – 2.30 <0.01* 1.62 0.84 – 3.21 0.16
CCI at admission, score 1.13 1.00 – 1.29 <0.1* 1.08 0.93 – 1.26 0.39
NYHA**: Class I or II (reference) 1 – –
NYHA: Class III 0.72 0.26 – 2.02 0.52 - - -
NYHA: Class IV 2.62 0.95 – 7.27 <0.1* 2.15 1.00 - 4.59 <0.1*
Hypertension at admission, yes 0.85 0.43 – 1.65 0.63 - - -
Log10(NT-proBNP) at discharge, pg/mL 2.75 1.32 – 5.75 <0.05* 1.69 1.07 – 2.76 <0.05*
Sinus rhythm at admission, yes 1.17 0.60 – 2.28 0.65 - - -
LVEF ≤40 at discharge % 1.48 0.72 – 3.04 0.3 - - -
Main presentation: - - -
- Severe peripheral oedema, yes 1 – –
- Severe breathlessness at rest, yes 0.42 0.15 – 1.14 0.11
- Increasing exertional breathlessness, yes 0.48 0.18 – 1.25 0.13
- Chest pain - cardiac, yes 0.26 0.05 – 1.31 0.11
- Other symptom, yes 0.35 0.04 – 2.93 0.33
HF Medication at admission
- ACE inhibitor, yes 1.67 0.86 – 3.25 0.13 - - -
-ARB, yes 1.27 0.58 – 2.79 0.56 - - -
-Beta-blocker, yes 2.54 1.22 – 5.29 <0.1* 1.86 0.87 –3.99 0.15
-Aldosterone Antagonist, yes 2.27 1.13 – 4.58 <0.1* 1.69 0.79 – 3.62 0.18
-Digitalis, yes 1.36 0.56 – 3.27 0.5 - - -
-Diuretics, yes 2.44 1.17 – 5.09 <0.05* 1.1 0.48 – 2.53 0. 82
HR, Hazard Ratio; CI, Confidence Interval; NYHA, New York Heart Association;
CCI, Charlson comorbidity index; LVEF, Left ventricular ejection fraction;
ACE, Angiotensin-converting enzyme; ARB: Angiotensin Receptor Blockers.
*significance level of 0.1
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DISCUSSION
Amongst patients admitted to hospital with worsening heart failure, the presence of
moderate to severe depression is a strong predictor of mortality subsequent to dis-
charge, even after correcting for potential confounders. This is consistent with ev-
idence suggesting that depression predicts mortality amongst patients with chronic
HF [2, 3] but the relationship may be even stronger for those admitted to hospital with
worsening heart failure.
Whether the association between depression and mortality is causal and, if so, whether
targeting this link could improve prognosis remains uncertain. Pessimism and depres-
sion may have biological effects that adversely affect prognosis [10]. Alternatively, de-
pression may reduce adherence to lifestyle advice and heart failure medications lead-
ing to a worse prognosis [11, 12]. Health care professionals might be unconsciously
less attentive to depressed patients. Finally, it is possible that we did not identify and
measure some key prognostic variables; some patients may be depressed because they
not only feel sicker but are indeed sicker. The clinical reality is that all of the above are
probably relevant to different patients at different times. Teasing out which is the most
important for an individual patient may be difficult.
It is unclear whether the recognition and management of depression might improve
patient outcomes. Randomized trials of drug intervention with selective serotonin re-
uptake inhibitors have been disappointing [13, 14]. Interestingly, many patients admit-
ted to hospital with worsening heart failure report good quality of life after discharge
[15]. Maybe improving the patients’ perception of their future and their enjoyment of
their lives would have a positive feedback that improves outcome. Perhaps the focus
should also be on serial assessment with intervention only when depression persists
despite simple measures such as good treatment of the medical condition, social sup-
port and attention to health fears and loneliness. Trials of new interventions, such as
cognitive behavioral therapy, use of self-management plans delivered by community
health care teams or by tele-monitoring might be effective alternatives to drug therapy
[16]. Tackling the problems that depression causes rather than depression itself could
also be important; a diagnosis of depression should heighten awareness of the need
for support, advice and encouragement of adherence.
Mild depression was not strongly associated with mortality in either the univariable
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or multivariable models. This may reflect the attributes of the HADS score; several
questions could reflect the severity of functional impairment due to HF itself rather
than depression. For instance, one question asks the patient to rate this statement
“I feel as if I am slowed down”; most patients gave themselves poor scores on this
question, which could be interpreted as the inability to exercise due to heart failure:
however, it leads to patients being given a HADS score suggesting mild depression.
Most patients gave themselves a worst-rank score for the statement “I can laugh and
see the funny side of things”. For other questions, there was a wider distribution of
scores. It is not clear that the relatively complex questionnaires currently used to assess
mood and quality of life are superior to single, simple, direct, intuitive questions in
detecting important depression (“Are you depressed? If so, how badly does this affect
you?”) or assessing well-being (“On a scale of 1−10 how well are you today?”); single
questions are easy to administer and may be more efficient, although they may need
to be interpreted in the context of the patients situation (for example, recent near-
death experience, worsening heart failure or stable CHF) [17]. Indeed, responses to just
two-questions (PHQ−2) appears to identify patients with depression fairly accurately
compared to more complex instruments [18].
Other Limitations. The study is relatively small, with a modest number of events, but
it is one of the first in patients hospitalized with worsening HF. The diagnosis of de-
pression was made with a tool that does not give the same diagnostic certainty as
DSM-III/IV or similar codes. The tool was only administered once, and we may have
missed changes in mood during or after hospitalization. The HADS uses some collo-
quial language which may not be understood by patients from different backgrounds.
Conclusion. Moderate to severe depression is strongly associated with mortality in the
year following discharge after a HF admission to hospital. The association is indepen-
dent of HF severity and other comorbidity. New strategies are required to improve
the recognition of depression and to target those with persistent problems who might
benefit from intervention.
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APPENDIX A: CHARLSON COMORBIDITY INDEX (CCI)
Comorbidity is assessed by Charlson Comorbidity Index (CCI) [19]. CCI is calculated
during hospitalization by assigning to certain comorbidities a weighted value.
• 1 point: Myocardial infarction, congestive heart failure, peripheral vascular dis-
ease, dementia, cerebrovascular disease, chronic pulmonary disease, connective
tissue disease, ulcer disease, mild liver disease, diabetes.
• 2 points: Hemiplegia, moderate or severe renal disease, diabetes with end organ
damage, any tumor, leukemia, lymphoma.
• 3 points: Moderate or severe liver disease.
• 6 points: Metastatic solid tumor, AIDS.
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APPENDIX B: HADS-D QUESTIONNAIRE ITEMS
In this analysis the depression related part of the HADS questionnaire is used. This
part consists of the following seven questions and four possible answers per question.
1. I still enjoy the things I used to enjoy
(a) Definitely as much
(b) Not quite so much
(c) Only a little
(d) Hardly at all
2. I can laugh and see the funny side of things
(a) As much as I always could
(b) Not quite so much now
(c) Definitely not so much now
(d) Not at all
3. I feel cheerful
(a) Not at all
(b) Not often
(c) Sometimes
(d) Most of the time
4. I feel as if I am slowed down
(a) Nearly all the time
(b) Very often
(c) Sometimes
(d) Not at all
5. I have lost interest in my appearance
(a) Definitely
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(b) I don’t take so much care as I should
(c) I may not take quite as much care
(d) I take just as much care as ever
6. I look forward with enjoyment to things
(a) As much as ever I did
(b) Rather less than I used to
(c) Definitely less than I used t o
(d) Hardly at all
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APPENDIX C: CONSORT DIAGRAM
The consort diagram of the study is shown in Figure 3.2).
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Chapter 4. Prognostic value of psychosocial factors for recurrent events
ABSTRACT
Aims: Psychosocial factors are rarely collected in studies investigating the prognosis
of patients with heart failure (HF), and only time to first-event is commonly reported.
We investigated the prognostic value of psychosocial factors for predicting first or
recurrent events after discharge following hospitalization for HF.
Methods and results: OPERA-HF is an observational study enrolling patients hospi-
talized for HF. In addition to clinical variables, psychosocial variables are recorded.
Patients provide the information through questionnaires which include social infor-
mation, depression and anxiety scores, and cognitive function. Kaplan-Meier, Cox
regression and the Andersen-Gill model were used to identify predictors of first and
recurrent events (re-admissions or death).
Of 671 patients (age 76±15 years, 66% men) with one-year follow-up, 291 had no sub-
sequent event, 34 died without being readmitted, 346 had one or more unplanned
readmissions and 71 patients died after a first readmission. Increasing age, higher
urea and creatinine, the presence of co-morbidities (diabetes, history of MI, COPD),
were all associated with increasing risk of first or recurrent event. Psychosocial vari-
ables independently associated with both the first and recurrent events were: presence
of frailty, moderate to severe depression and moderate to severe anxiety. Living alone
and the presence of cognitive impairment were independently associated only with
an increasing risk of recurrent events.
Conclusion: Psychosocial factors are strongly associated with unplanned recurrent
readmissions or mortality following an admission to hospital for HF. Further research
is needed to show whether recognition of these factors and support tailored to indi-
vidual patients’ needs will improve outcomes.
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INTRODUCTION
Patients with heart failure (HF) are at high risk of readmissions and death. About 25%
of patients admitted with HF are readmitted within one month of leaving hospital
[1]. In European studies, the readmission rate is up to 44% at 1 year after discharge
[1]. Commonly, studies investigating risk factors for readmission only consider the
first readmission. However, they are often recurrent, reflecting progression of the un-
derlying disease or exacerbations due to co-morbidities and sub-optimal self-care and
medication adherence. Understanding the causes, precipitants and risk factors for re-
current readmissions may help to prevent them. By focusing only on first event anal-
ysis, any subsequent events are ignored and the impact of potential risk factors can be
greatly under- or over- estimated.
Several demographic or clinical variables, such as age, sex, the presence of co-morbidi-
ties, left ventricular ejection fraction, New York Heart Association class of symptoms
and serum markers are important predictors of readmissions and death among pa-
tients with HF [2]. The impact of psychosocial factors on first readmission or mortality
has also been studied [3]. The presence of psychosocial factors, such as depression, is
significant predictor of mortality among patients with HF [4, 5]. The presence of frailty
is also associated with increasing risk of first readmission or mortality [6, 7]. However,
there is no report about the effect of depression, frailty and other psychosocial factors
on recurrent events.
Accordingly, we explored the effect of psychosocial factors on first and recurrent un-
planned readmissions or death in a cohort of patients discharged after a hospitaliza-
tion for worsening HF.
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METHODS
Study design
OPERA-HF is an ongoing prospective observational study, enrolling patients hos-
pitalized for HF in the Hull & East Yorkshire Hospitals NHS Trust, UK. The aim
of the study is to create a holistic view of the patients, their general condition and
co-morbidities, and to identify predictors of mortality and re-admission to hospital.
Additional assessments, including assessments of depression/anxiety and cognitive
function, were performed during hospital admission using questionnaires completed
by the patient.
Patients had to fulfill all of the following criteria to be included in the present study:
age > 18 years; usual residence in the region served by the Hull & East Yorkshire
Hospitals Trust; hospitalization for HF; treatment with loop diuretics; and at least one
of the following: left ventricular ejection fraction (LVEF) ≤ 40%, left atrial dimension
>4.0 cm [8] or NT-ProBNP > 400 pg/ml (if in sinus rhythm) or > 1200 pg/ml (if in
atrial fibrillation) [9]. Patients who were unable to understand and comply with the
protocol or unable or unwilling to give informed consent were not included in the
study. The study has full ethical approval from the South Yorkshire Research Ethics
Committee (REC ref: 12/YH/0344) and is conducted in accordance with ICH-GCP,
Declaration of Helsinki, the Data Protection Act 1998 and the NHS Act 2006.
Depression and anxiety assessment
Depression and anxiety were assessed by the Hospital Anxiety and Depression Scale
(HADS) questionnaire [10]. The HADS consists of two parts of 7 questions each, one
focusing on depression and one on anxiety. For each part, the response to each of
the 7 questions is graded from 0 to 3, giving a total score that ranges between 0 and
21. A score of 7 or less implies that there is no depression or anxiety; a score of 8-10
suggests mild depression or anxiety; and a score of 11 or more reflects moderate-to-
severe depression or anxiety [10].
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Cognition assessment
This assessment was based on the General Practitioner assessment of Cognition, [11]
a brief screening tool for detecting cognitive impairment. It was designed for use by
primary care practitioners. The cognitive test includes nine items focusing on time
orientation, clock drawing, awareness of a current news event and recall of a name
and an address. Each correct answer scores one point leading to a maximum score of
9. A score of 4 or lower indicates cognitive impairment.
Frailty
For frailty, a two-fold assessment was applied. First the patient was asked to respond
to a question about having troubles bathing or dressing and then was assessed through
the ‘get up and go’ test. The timed ‘get up and go’ requires patients to stand up from a
chair, walk a short distance (3 m), turn around, return, and sit down again. The normal
time to complete the task is less than 10 seconds and abnormal is more than 20 seconds
[12]. Patients who reported either troubles in bathing or dressing or completed the ‘get
up and go’ test in more than 20 seconds were defined as frail.
Readmission/Mortality
All patients enrolled in the study are followed subsequent to discharge. All-cause
readmissions and mortality are automatically recorded in the hospital’s IT system.
For the present report, the primary outcome of interest was all-cause unplanned read-
missions or mortality. Unplanned readmission is considered any type of emergency
readmission such as emergency fast-track, through the Accident and Emergency de-
partment, or an urgent admission requested by the GP.
Statistical analysis
We report the baseline characteristics of the patients who participated in the study
between October 2012 and July 2016. Follow up was censored at August 2016. We
describe and compare the baseline characteristics of the patients by the number of
their subsequent events. For the comparison among patients having no event with
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patients having one or multiple readmissions or death after discharge, we used the
chi-squared test to compare binary or categorical variables, and Kruskal-Wallis test
for continuous variables. In order to avoid comparisons between groups of patients
with unequal follow up times, we initially analysed events in patients for whom one
year follow up data were available, including only those events which happened in
the first year, in order to compare those with and those without an event.
We subsequently included all patients in statistical modeling to determine the relation
between a putative risk factor and outcome. The Kaplan-Meier method was used to
estimate the cumulative incidence of events (readmissions and mortality) [13]. The
event rate was calculated by taking into account all available recurrent events. We
used univariable Cox regression to calculate the effect of potential risk factors on the
first unplanned readmissions or death. The Andersen-Gill model was used to analyze
the effect of the same factors when taking into account recurrent unplanned readmis-
sions or death. The counting processes model of Andersen-Gill is a semiparametric
model, and is a generalization of the Cox regression model [14]. It takes into account
all the recurrent events along the time line, where the time to an event starts at the end
of the previous event. All events are treated as being similar and independent of each
other.
After identifying predictors of outcome, we calculated the effect of each psychosocial
variable whilst adjusting for all significant clinical ones. For the psychosocial variables
we used only complete cases and for clinical variables we used multiple imputation to
impute missing values [15]. Application of the technique requires three steps: imputa-
tion, analysis and pooling. Each missing clinical value was imputed 5 times following
the predictive mean matching method, thus producing 5 imputed data sets; each one
of these 5 imputed data sets was then analyzed by the aforementioned complete-data
procedures. The 5 resulting analyses are then combined into one final analysis fol-
lowing Rubin’s method. The means of these pools are reported in the result section
[15, 16]. All analyses were conducted using R 3.3.2 statistical software (The R Founda-
tion for Statistical Computing, Vienna, Austria).
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RESULTS
Of 814 patients consented, 35 died during the index admission and 779 were dis-
charged. (Consort diagram: Figure 4.1) The median follow up amongst survivors was
764 (interquartile range, IQR 411–1069) days. 671 patients either died during the first
year or were still alive at one year. The remaining 108 patients were survivors who
had not yet completed their first year follow up after discharge.















35 died in hospital
First year follow up
Figure 4.2 shows the outcomes at one year for the 671 patients who had at least one
year follow-up or who died within one year and consequently had known one year
outcome. During the first year, 291 (43%) patients had no event; 34 (5%) patients died
without being readmitted; 346 (52%) had at least one unplanned readmission and 125
(19%) died after one or more further admissions.
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FIGURE 4.2: Diagram of events within first year of discharge, based on 671 patients
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Of patients who agreed to complete the psychosocial assessments, 35% had all assess-
ments completed and 54% had at least 4 of them completed. Patients who had no
events in the first year were younger, and were less likely to have a history of MI or
COPD (Table 4.1).
Patients with one or more follow up events were more likely to have moderate-to-
severe depression or moderate-to-severe anxiety and were more likely to be frail; they
were less likely to complete the “get up and go” test and were more likely to report
difficulties in bathing or dressing.
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All follow up
Figure 4.3 shows events for all 779 participants, including patients followed for less
than one year and events that happened after the first year. Overall, 220 (28%) pa-
tients had no event; 41 (5%) died without being readmitted; 518 (66%) had at least one
unplanned readmission and 228 (29%) died after one or more further admissions.
The incidence of unplanned readmission and mortality is shown in Figure 4.4, with a
combined event rate of 70% [95% CI 68% - 72%] at one year.
FIGURE 4.3: Diagram of all events for 779 patients discharged after the index-





Died: 41 patients 
died without being 
readmitted 
1st readmission: 
518 patients had 
at least one 
Censored: 220 
patients had no 
follow up event 
Died: 88 patients  
2nd readmission: 
307 patients  
Censored: 123 
patients  
Died: 54 patients  
3rd readmission: 
179 patients  
Censored: 74 
patients  




Chapter 4. Prognostic value of psychosocial factors for recurrent events
TABLE 4.1: Baseline characteristics for all study participants and all participants with
follow up at one year stratified by number and type of events. Characteristics are
summarized by their count and fraction (N (%)) for categorical or their median and
interquartile range (Median [25th – 75th]) for continuous variables respectively; (*)
0.1 level of significance; (**) NYHA class which was evaluated as the worst class dur-
ing the last 7-days before admission; (***) the closest measurement to discharge. N =
number of patients with this variable available
All patient data Patients with one year follow-up data
Event All All No Events One Death/ No >1 event Compa-
re-admission re-admission rison
(N = 779) (N = 671) (N = 291) (N=121) (N = 34) (N = 225)
Characteristics N N P-value*
Women, % 779 271(35%) 671 230(34%) 109(37%) 47(39%) 7(21%) 67(30%) 0.15
Age, years 779 75[67-82] 671 76[67-82] 73[64-80] 75[68-81] 79[73-86] 78[71-84] <0.01
Diabetes, % 779 278 (36%) 671 243 (36%) 101 (35%) 45(37%) 14(48%) 83(37%) 0.53
History of MI, % 779 183 (23%) 671 163(24%) 57(20%) 34(28%) 12(35%) 60(27%) <0.05
COPD, % 779 136(17%) 671 111(17%) 35(12%) 21(17%) 7(21%) 48(21%) <0.01
Cancer, % 779 69(10%) 671 72(10%) 31(11%) 16(13%) 2(6%) 20(9%) 0.88
NYHA **: 672 569
Class I/II, % 68(10%) 67(12%) 29(12%) 14(14%) 0(0%) 24(12%) 0.61
NYHA: Class III, % 427(64%) 365(64%) 163(67%) 70(71%) 20(74%) 112(56%)
NYHA: Class IV, % 177(26%) 137(24%) 52(21%) 15(15%) 7(26%) 63(32%)
Hypertension at ADM,% 726 359(58%) 622 359(58%) 163(59%) 64(55%) 17(55%) 115(57%) 0.48
NT-proBNP, pg/mL*** 664 4300 570 4599 3931 4280 6369 5414 0.46
[1803−9456] [1934-9553] [1894−7954] [1576-9023] [3884-16657] [2083-10843]
Sinus rhythm at DIS % 779 286(37%) 671 250(37%) 115(40%) 39(32%) 12(35%) 84(37%) 0.33
LVEF ≤40% at DIS, % 683 286(42%) 588 241(41%) 95(37%) 51(47%) 13(45%) 82(42%) 0.11
Main presentation: 768 660 0.48
-Severe peripheral 59(8%) 50(8%) 20(7%) 6(5%) 5(16%) 19(9%)
oedema, %
-Severe breathlessness 225(29%) 204(31%) 94(34%) 36(30%) 8(25%) 64(29%)
at rest,%
-Increasing exertional 356(46%) 285(43%) 115(40%) 53(44%) 17(53%) 100(45%)
breathlessness, %
-Chest pain-cardiac, % 72(9%) 67(10%) 28(10%) 16(13%) 2(6%) 21(9%)
-Other symptom % 56(7%) 54(8%) 24(9%) 10(8%) 0(0%) 17(8%)
Urea at DIS, 776 9[7-14] 669 9[6-14] 8[6 -11] 9[6-14] 18[11-25] 11[8-15] 0.17
Creatinine at DIS, 774 106[84-141] 668 106[84-143] 97[80-125] 104[86-141] 161[111-210] 119[91- 157] 0.26
µmol/L
Depression HADS 371 300 <0.05
-None-to-mild, % 316(85%) 255(85%) 122(91%) 44(83%) 13(81%) 76(78%)
-Moderate-to-severe, % 55(15%) 45(15%) 12(9%) 9(17%) 3(19%) 21(22%)
Anxiety HADS 366 296 <0.01
-None-to-Mild, % 300(82%) 243(82%) 120(89%) 35(70%) 14(87%) 74(78%)
-Moderate-to-severe,% 66(18%) 53(18%) 15(11%) 15(30%) 2(13%) 21(22%)
GPCOG score≤4, % 380 28(7%) 315 25(8%) 7(5%) 2(4%) 3 (18%) 13(13%) 0.11
Living alone, % 660 218(33%) 566 184(33%) 74(30%) 32(30%) 9(36%) 69(33%) 0.29
Trouble bathing/ 644 157(24%) 553 134(24%) 46(19%) 24(23%) 10(42%) 54(30%) <0.05
dressing, %
Get up and go test:
-Able to complete % 614 285 (46 %) 520 242 (46 %) 116 (51 %) 40 (42 %) 7 (29 %) 79 (45 %) <0.1
Time to complete, sec 285 9 [6 - 15] 242 10 [6 - 16] 8 [6 - 12] 11 [8 - 20] 15 [4 - 22] 12 [8 - 20] 0.14
MI Myocardial infarction; NYHA New York Heart Association; ADM admission; DIS discharge; LVEF left ventricular ejection
fraction; HADS Hospital Anxiety and Depression Scale; GPCOG General Practitioner assessment of Cognition.
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FIGURE 4.4: Cumulative incidence plot of events; recurrent readmissions and mor-
tality. For the plot gap times are used. That means that every recurrent event of a
patient is taken into account as a new sample for the calculations starting from point
zero. Dotted grey lines: incidence rate at 1 year; Dotted black lines: 95% confidence
interval.
Risk factors for first event
There were 559 first events (41 deaths and 518 readmissions). Increasing age, a past
history of MI or COPD, LVEF lower than 40%, and increasing urea and creatinine at
discharge were all associated with increasing risk of first event. Amongst psychosocial
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variables, moderate-to-severe depression, moderate-to-severe anxiety, worsening cog-
nitive impairment and the presence of frailty were all associated with adverse events
(Table 4.2a).
Risk factors for recurrent events
There was a total of 1600 events including 1041 events subsequent to the first. In-
creasing age, history of MI, the present of diabetes or COPD, and increasing urea and
creatinine at discharge were all associated with increasing risk. Amongst psychosocial
variables, moderate-to-severe depression or anxiety, cognitive impairment and frailty,
assessed by a question on troubles with bathing/dressing and/or by the ‘timed get
up and go’ test, were all also associated with adverse events. Patients living alone
also had a significantly higher risk (although not facing an increased risk of first event
alone) (Table 4.2b).
Impact of psychosocial factors adjusted for demographic and clinical variables
In the statistical models adjusting for the clinical variables found to be significant in
the univariable analysis (age, diabetes, history of MI, COPD, urea and creatinine),
moderate-to-severe depression, moderate-to-severe anxiety, cognitive impairment, the
presence of frailty and living alone were significant predictors of adverse outcomes
(Table 4.3).
Patients having troubles with bathing or dressing were 20% more likely to have one
or more follow-up events compare to those not reporting troubles. Patients able to
complete the “get up and go” test were 20% less likely to have a first follow up event
than those who could not. Being unable to complete the test was a significant predic-
tor of a first event, but not of recurrent events. Amongst those who did manage to
complete the test, there was a 1% increase in risk of first or recurrent events for every
extra second taken.
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TABLE 4.2: (a) Univariable Cox regression model for first unplanned readmission or
death (b) Univariable Anderson-Gill model for recurrent events. (*) 0.1 level of signif-
icance; (**) NYHA class which was evaluated as the worst class during the last 7-days
before admission; (***) the closest measurement to discharge
(a) First event only (b) Recurrent events
(N/events) HR 95% CI p-value* (N/events) HR 95% CI p-value*
Women, yes (779/559) 0.97 0.82-1.15 0.7 (2110/1600) 1.06 0.88-1.27 0.53
Age, years (779/559) 1.24 1.15−1.35 <0.001 (2110/1600) 1.29 1.16−1.43 <0.001
Diabetes, yes (779/559) 1.1 0.93−1.30 0.28 (2110/1600) 1.34 1.12 − 1.59 <0.001
History of MI, yes (779/559) 1.29 1.07−1.55 <0.01 (2110/1600) 1.33 1.10−1.62 <0.01
COPD, yes (779/559) 1.43 1.14−1.79 <0.01 (2110/1600) 1.5 1.20−1.89 <0.001
Cancer, yes (779/559) 0.97 0.74−1.27 0.83 (2110/1600) 1.04 0.78−1.40 0.77
NYHA **: Class I or II, yes (672/468) 1 - - (1785/1343) 1 - -
NYHA: Class III, yes 1.05 0.76−1.44 0.77 1.1 0.81−1.49 0.53
NYHA: Class IV, yes 1.19 0.85−1.68 0.31 1.29 0.92−1.81 0.14
Hypertension at ADM, yes (726/515) 1.03 0.86 - 1.23 0.73 (1957/1477) 1.04 0.86-1.25 0.7
Log(NT-proBNP),pg/mL*** (664/477) 1.05 0.98−1.14 0.17 (1833/1396) 1.02 0.96−1.12 0.32
Sinus Rhythm at DIS, yes (779/559) 0.91 0.76-1.08 0.28 (2110/1600) 0.95 0.79−1.13 0.57
LVEF ≤40% at DIS, yes (683/479) 1.2 1.00−1.44 <0.05 (1845/1395) 1.17 0.97−1.41 0.1
Main presentation: (768/548) (2076/1571)
-Severe peripheral 1 - - 1 - -
oedema, yes
-Severe breathlessness 0.94 0.64 − 1.38 0.74 0.84 0.59−1.20 0.35
at rest, yes
-Increasing exertional 1.07 0.74 − 1.56 0.71 1.02 0.73−1.45 0.89
breathlessness, yes
-Chest pain - cardiac, yes 1.11 0.72−1.70 0.64 1 0.65−1.53 1
-Other symptom, yes 1.06 0.68−1.64 0.81 0.92 0.61−1.37 0.67
Urea at DIS, mmol/L (776/557) 1.27 1.15−1.40 <0.001 (2099/1590) 1.25 1.15−1.36 <0.001
Creatinine at DIS, µmol/L (774/556) 1.54 1.38−1.72 <0.001 (2094/1587) 1.54 1.39−1.72 <0.001
Depression HADS (371/227) (866 / 596)
-None-to-mild, yes 1 − − 1 − −
-Moderate-to-severe, yes 1.73 1.24 − 2.41 <0.01 1.76 1.25 - 2.47 <0.001
Anxiety HADS (366/222) (848/581)
-None-to-mild, yes 1 − − 1 − −
-Moderate-to-severe, yes 1.64 1.24−2.18 <0.001 1.37 1.03-1.84 <0.05
GPCOG score (380/232) 1.7 1.06 − 2.71 <0.05 (903/628) 1.58 1.00−2.50 <0.1
Living alone yes (660/465) 1.14 0.94 - 1.39 0.18 (1781/1341) 1.37 1.12−1.67 <0.01
Trouble bathing (644/453) 1.48 1.20−1.83 <0.001 (1736/1303) 1.27 1.02−1.57 <0.05
or dressing, yes
Get up and go test:
-Able to complete, yes (614/421) 0.72 0.59−0.87 <0.001 (1646/1229) 0.81 0.66−0.99 <0.05
-Time to complete, sec (285/169) 1.02 1.01−1.03 <0.001 (701/495) 1.02 1.01−1.03 <0.001
N, number of patients with available data for this variable; HR, hazard ratio; CI, confidence interval,
NYHA, New York heart association; ADM, admission; DIS, discharge; LVEF, left ventricular ejection fraction;
HADS, hospital anxiety and depression scale; GPCOG, general practitioner assessment of cognition
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TABLE 4.3: (a) Adjusted Cox regression model for first unplanned readmission or
death (b) Adjusted Anderson-Gill model for recurrent events. (*) 0.1 level of signif-
icance; (**) each variable is adjusted for the most significant (P<0.01) clinical variables
including age, diabetes, history of MI, COPD, urea and creatinine at discharge (see
Table 4.2)
(a) First event only ** (b) Recurrent events **
HR 95% CI p-value* HR 95% CI p-value*
Depression HADS
-None-to-mild, yes 1 − − 1 − −
-Moderate-to-severe yes 1.74 1.24 - 2.44 <0.01 1.77 1.44 - 2.17 <0.001
Anxiety HADS
-None-to-mild, yes 1 − − 1 − −
-Moderate-to-severe, yes 1.67 1.21 - 2.30 <0.01 1.35 1.11 - 1.65 <0.01
GPCOG score ≤ 4, yes 1.43 0.90 − 2.28 0.12 1.4 1.06 − 1.85 <0.05
Living alone, yes 1.04 0.85 − 1.27 0.71 1.24 1.11 − 1.39 <0.001
Trouble bathing or 1.33 1.07 − 1.65 <0.01 1.18 1.04 − 1.35 <0.05
dressing, yes
Get up and go test:
-Able to complete, yes 0.81 0.66 − 0.99 <0.05 0.95 0.84 − 1.07 0.38
-Time to complete, sec 1.02 1.01 − 1.03 <0.01 1.01 1.01 − 1.02 <0.001
HR, hazard ratio; CI, confidence interval; HADS, hospital anxiety and depression scale;
GPCOG, general practitioner assessment of cognition.
The impact of psychosocial variables on outcomes is plotted in Figure 4.5, with the
patients grouped by having none or at least one of the following factors: moderate-
to-severe depression; moderate-to-severe anxiety; cognitive impairment; more than 20
seconds needed to complete the ‘get up and go’ test; troubles with bathing or dressing;
or living alone.
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FIGURE 4.5: Cumulative incidence plot of events (recurrent readmissions and mortal-
ity) of patients having at least one psychosocial factor assessed negatively compared
to those with none, adjusted for significant demographic and clinical factors. We used
data of the 477 patents who had participated to at least one of the psychosocial assess-
ments.
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DISCUSSION
Our study is one of the first to evaluate the impact of psychosocial factors on the risk
of subsequent events in patients hospitalized for heart failure (HF). We found a high
event rate, with 70% of patients being re-admitted or dying at one year follow up.
In common with previous studies, we have found that older patients with more co-
morbidities, or higher urea or creatinine, are more likely to have one or more un-
planned events. We also found that the presence of frailty, anxiety and depression
were powerful predictors of outcome, both of first and of recurrent events.
We have previously reported that depression is strongly associated with increasing
mortality in this cohort [4]. In the present study, we have found that patients with
moderate-to-severe anxiety have a 1.7 times higher risk of a first event and a 1.4 higher
risk of recurrent events compared to patients without anxiety. Patients with moderate-
to-severe depression have a 1.7 times higher risk of a first event and a 1.8 higher risk
of recurrent events compared to patients without depression. Patients living alone
or with cognitive impairment have a 1.2 and 1.4 times higher risk of having multiple
events after discharge compared to the patients not living alone or without cognitive
impairment, respectively.
Psychological factors such as depression [17, 18] and other factors not directly related
to the medical reason for an admission to hospital, such as cognitive impairment [19]
or frailty [20], are associated with adverse events in older people. We have found that
these are also powerful predictors of adverse outcomes amongst patients hospitalized
with HF. We also showed that the presence of at least one adverse psychosocial fac-
tor was associated with 1.8 higher risk of one or more recurrent events compared to
having none.
Frailty is increasingly recognized as an important factor in managing patients with
long term conditions [21], but although it is easily recognized clinically, it can be diffi-
cult to define. Increasing age is an obvious risk factor for frailty, and around a quarter
of patients admitted to hospital for HF are over 80 years of age [22]. Frailty is associ-
ated with poor nutritional status, itself associated with worse long-term outcome [23].
There are recent studies concluding that an indicator of frailty in routine care is related
to first readmission or mortality in HF patients [7] or that amongst patients hospital-
ized for HF, worsening frailty measured by screening tools, such as the Derby frailty
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index (DFI) or clinical frailty scale (CFS), is strongly related to increasing mortality
[24]. The results of the present study show a strong association between the presence
of frailty and the risk of follow up. Even the answer to a simple question about diffi-
culties with daily activities has a similar predictive value as more elaborate screening
tools. We also found that the ‘get up and go’ test, a simple test of mobility, is strongly
related to outcome. For every extra second needed to complete the test the risk of re-
current events increased by 1%. As an indicator of “social frailty”, living alone was
also associated with a worse outcome.
Previous studies have not found an association between anxiety and mortality in HF
although depression is associated with worse outcomes [4]. We found that both de-
pression and anxiety are related to the risk of recurrent events. The mechanism is
not clear, but may be related to the reduced self-care seen amongst patients with de-
pression [25]. Further research is needed to see if any specific intervention targeted at
psychological factors is helpful. Anti-depressant therapy in patient with HF does not
affect mortality and morbidity [26] but psychotherapy in primary care has a limited
beneficial effect on reducing depression in patients with a cardiac condition [27].
Cognitive impairment is a risk factor for adverse events in patients with HF [28]. We
found that cognitive impairment is also associated with an increased risk of recurrent
post discharge events. Cognitive impairment is also an impediment to HF patients’
ability to self-care [29].
We have thus found that a range of related conditions not directly associated with
the HF syndrome itself – frailty (both physical and social), cognitive impairment, de-
pression and anxiety – are all associated with an increased risk of adverse outcomes
following discharge from hospital after an admission for HF. The individual patient
should always be treated within his or her individual social context, and proper man-
agement should always consider whole patient, something of which it can be easy to
lose sight in a busy hospital.
It is not clear from the present study whether targeted interventions for the condi-
tions we have identified as predictors of a poor outcome might have a beneficial ef-
fect. Multidisciplinary interventions have shown some evidence of benefit [30] and
exercise therapy can also help in frail subjects [31]. Intervention trials are needed to
see whether such interventions as providing extra help at home, day care or telemon-
itoring might be helpful.
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Limitations. The Anderson-Gill approach assumes the recurrent events to be identically
distributed and independent of each other, which might not always be the case. It also
treats death as an event similar to readmission. Missing data is also a limitation in
this study. However, there is evidence to support the method that we followed to
impute part of the data [15]. Our analysis is based on patients hospitalized only in one
location. Further external validation of the results is needed in order to support their
generalizability.
Our methods have been developed for research and have not been extensively tested
in routine practice for HF patients. The HADS survey will not give the same diagnostic
certainty as ICD-9 or similar codes. The surveys were only administered once, and we
may have missed changes during or after hospitalization or subsequent events. The
questionnaires use some colloquial language which may not be understood by patients
from different backgrounds.
Conclusion. Moderate-to-severe depression and anxiety, living alone, cognitive im-
pairment and the presence of frailty are strongly associated with unplanned recurrent
admissions and mortality in the year following discharge after a HF admission to hos-
pital. Studies are needed to show whether strategies to support patients from a social
perspective and to target those with persistent problems with appropriate non-clinical
interventions help to reduce risk.
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Chapter 5. The OPERA 30-day prediction model
ABSTRACT
Aims: Models for predicting the outcome of patients hospitalized for heart failure
(HF) rarely take a holistic view. We assessed the ability of measures of frailty and
social support in addition to demographic, clinical, imaging and laboratory variables
to predict short-term outcome for patients discharged after a hospitalization for HF.
Methods and results: OPERA-HF is a prospective observational cohort, enrolling pa-
tients with a discharge diagnosis of HF from a single center in Hull, UK. Variables were
combined in a logistic regression model after multiple imputation of missing data to
predict the composite outcome of death or readmission at 30 days. Comparisons were
made to a model using clinical variables alone. The discriminative performance of
each model was internally validated with bootstrap re-sampling.
1094 patients were included (mean age 77 [interquartile range 68 – 83] years; 40%
women; 56% with moderate to severe left ventricular systolic dysfunction) of whom
213 (19%) had an unplanned re-admission and 60 (5%) died within 30 days. For the
composite outcome, a model containing clinical variables alone had an area under the
receiver-operating characteristic curve (AUC) of 0.68 [95% CI 0.64 – 0.72]. Adding mar-
ital status, support from family and measures of physical frailty increased the AUC
(p<0.05) to 0.70 [95% CI 0.66 – 0.74].
Conclusion: Measures of physical frailty and social support improve prediction of
30-day outcome after an admission for HF, but predicting near-term events remains
imperfect. Further external validation and improvement of the model is required.
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INTRODUCTION
Patients with heart failure (HF) are often re-admitted to hospital shortly after discharge
[1, 2, 3], although only 15-30% of such events are due to worsening heart failure. Re-
peated admissions to hospital are associated with substantial impairment in a patient’s
quality of life, high costs and increased mortality [4]. Some re-admissions are poten-
tially avoidable and preventing them may benefit both patients and the health-care
system. Outcome may be partly determined by the severity of cardiac dysfunction,
but physical frailty, co-morbidity, anxiety and depression, cognitive dysfunction and
poor social support might also contribute. Focusing only on cardiac dysfunction may
reduce the ability to predict adverse outcomes and miss opportunities to prevent them.
Developing a holistic model that can predict which patients with HF are at high risk
of early re-admission or death, and identify possible treatment targets, might improve
management and reduce events. Currently there is no such model [5, 6]. Many predic-
tive algorithms have been designed, but those aiming to predict short-term composite
outcomes perform poorly compared to those designed to predict longer-term mortal-
ity [6, 7].
The OPERA-HF study was designed to collect a broad range of information on physi-
cal frailty, mood, cognitive function and social support amongst patients admitted for
the treatment of worsening HF to find out whether such measures improve prediction
of outcome compared to conventional clinical variables alone. The current analysis
focuses on 30-day outcomes.
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METHODS
Study design
OPERA-HF (An Observational registry to assess and PrEdict the in-patient course, risk
of Re-Admission and mortality for patients hospitalised for or with Heart Failure) is
a prospective observational study, enrolling consecutive, consenting patients hospi-
talized for HF in the Hull and East Yorkshire Hospitals NHS Trust, UK. The aim of
the study is to create a holistic view of the patients, their general condition and co-
morbidities, and to identify predictors of mortality and re-admission to hospital. Data
were collected during hospital admission and just prior to discharge. The Charlson co-
morbidity index (CCI) was used to assess co-morbidity [8]. Psycho-social information
including depression and anxiety, cognitive function and social support was collected
during hospitalization using questionnaires (see below for details).
Patients had to fulfill the following criteria to be included: age >18 years; usual res-
idence in the region served by the Hull and East Yorkshire Hospitals Trust; hospital-
ization for HF; treatment with loop diuretics; and at least one of the following criteria
to confirm a diagnosis of HF: left ventricular ejection fraction (LVEF) ≤ 40%, left atrial
dimension >4.0 cm [9] or NT-ProBNP >400 pg/ml if in sinus rhythm or >1200 pg/ml
if in atrial fibrillation [10]. Patients who were unable to understand and comply with
the protocol or unable or unwilling to give informed consent were not included in
the study. The study has ethical approval from the South Yorkshire Research Ethics
Committee (REC ref: 12/YH/0344) and was conducted in accordance with ICH-GCP,
Declaration of Helsinki, the Data Protection Act 1998 and the NHS Act 2006.
Depression and anxiety
To assess depression and anxiety we used the Hospital Anxiety and Depression Scale
(HADS) questionnaire [11], consisting of seven questions on depression and seven on
anxiety, each graded from 0 to 3, giving a total score ranging from 0 to 21 for each
emotional state. A score of 7 or lower, 8 to 10, and 11 or more, implies no, mild or
moderate-to-severe depression or anxiety.
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Cognitive impairment
We used the General Practitioner assessment of Cognition (GPCOG), a brief screening
tool for detecting cognitive impairment [12]. The cognitive test includes nine items
focusing on time orientation, clock drawing, awareness of a current news event and
recall of a name and an address. Each correct answer scores one point leading to a
maximum score of 9. A score of 4 or lower indicates cognitive impairment.
Physical frailty
Physical frailty was assessed by asking patients to complete a timed “get up and go”
test, which asks patients to stand up from a chair, walk a short distance (3 m), turn
around, return, and sit down again. Less than 10 seconds is normally needed to com-
plete the task, while more than 20 seconds indicates poor functional independence of
the patient [13, 14]. We defined patients as being frail if they were unable to complete
the test or took more than 20 sec to complete it. Patients were also defined as being
frail if they reported difficulties either bathing or dressing themselves.
There are several tools to assess physical frailty which have been extensively validated
in the literature. There is, however, no consensus on the best performing tool for
patients with HF [15]. We used the timed “get up and go” test because it is simple,
easy to use in routine care, correlates well with functional independence and other
reliable tools and has been proven to be reliable in patients with HF [14, 16].
Social support
We defined patients to have good social support when they were married, not liv-
ing alone or when they self-reported perceiving good or excellent support from their
family.
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Outcomes
Re-admissions and mortality were automatically recorded in the hospital’s IT system.
For the present report, the primary outcome of interest was all-cause, unplanned re-
admissions or mortality within 30-days of discharge. Unplanned re-admission was de-
fined as any type of emergency re-admission (including emergency fast-track, admis-
sion via the Accident and Emergency department, or an urgent admission requested
by the GP).
Statistical analysis
We analyzed data from patients who participated in the study between October 2012
and November 2016 excluding 51 patients who died during the index admission. Rec-
ommendations from the TRIPOD guidelines were followed for the model develop-
ment and reporting [17]. We compared the baseline characteristics of the patients hav-
ing and not having an event within 30 days of discharge. We used chi-squared testing
to compare binary or categorical variables between groups, and the Kruskal-Wallis
test for continuous variables.
We applied univariable and multivariable logistic regression analysis to relate patient
characteristics to unplanned re-admission or death within 30 days of discharge. Odds
ratios (OR) were calculated with 95% confidence intervals (CI). In both analyses, mul-
tiple imputation was used to impute missing data. This requires three steps: imputa-
tion, analysis and pooling. Each missing value was imputed five times following the
predictive mean matching method, thus producing five imputed data sets; each one of
these five imputed data sets was then analysed and the results were pooled into one
final analysis following Rubin’s method [18, 19].
After identifying the most important variables associated with the outcome in the uni-
variable analysis (p < 0.1), we applied the least absolute shrinkage and selection op-
erator (LASSO) technique [20] to select the set of predictors for the final multivariable
model. LASSO uses a cross-validation procedure to select the optimal value for the
shrinkage parameter λ. We developed and compared a holistic model including both
clinical and other measures with a reference model based on clinical variables alone
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[21]. Since multiple imputation was applied, we repeated all the analyses using a
dataset of patients for whom data were complete, and compared the results.
Discrimination refers to the ability to distinguish patients experiencing an event from
those who did not, and was quantified by the area under the receiver operating charac-
teristic curve (AUC). An AUC of 0.5 indicates no discriminative ability at all while an
AUC of 1 indicates perfect discrimination. Multivariable models were internally vali-
dated by a bootstrap procedure, by sampling with replacement for 200 iterations. For
each imputed data set, full models were developed in bootstrap samples and evalu-
ated in the original sample to estimate the statistical optimism in performance [22, 23].
Besides the composite outcome, we also assessed the model performance when taking
into account readmission only or death only as an outcome. To evaluate the prediction
of readmission only we excluded patients who died without being readmitted within
30-days from the analysis dataset. All analyses were conducted using R 3.3.3 statistical
software (The R Foundation for Statistical Computing, Vienna, Austria).
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RESULTS
Baseline characteristics of the study population
Of the 1145 patients enrolled in the study, 51 died in the hospital and 1094 survived to
discharge. (Figure 5.1) Median length of hospital-stay during the index admission was
10 [6 – 17] days. Of 1094 surviving to discharge, 33 died without being readmitted, 27
died after being readmitted and 186 did not die but had an unplanned re-admission
within 30 days. 51% of the unplanned readmissions were related to heart failure, 25%
to other cardiovascular reasons and 25% to non-cardiovascular problems. (Table 5.1)
At admission, 62% of patients were in NYHA functional class III and 30% in class
IV. Only 41% were in sinus rhythm and only 22% had a Charlson co-morbidity index
≤ 1, while 30% had a score ≥ 5. Most patients (86%) were retired and 36% lived
alone, 14% had moderate-to-severe depression, 17% had moderate-to-severe anxiety
and 24% reported problems with bathing or dressing. Only 36% were willing and able
to do a get-up-and-go test, although most who did the test managed it in < 20 seconds.
The median number of tablets prescribed increased from 9 to 12 pills per day between
admission and discharge.
TABLE 5.1: Baseline characteristics and outcomes of the study cohort (N = 1094). Char-
acteristics are summarized by their count and fraction (N (%)) for categorical or their
median and interquartile range (Median [25th – 75th]) for continuous variables, re-
spectively
All Re-admitted No events Compare
or died within with and
in 30 days 30 days w/o events
Valid (N = 1094) (N = 246) (N = 848)
Characteristics N Summary Summary Summary p-value*
Demographics
Age, years 1094 77 [68 − 83] 79 [72 − 85] 76 [67 − 82] <0.001
Women, % 1094 433 (40%) 100 (41%) 333 (39%) 0.75
Vital signs at hospital admission and other measurements
Continued on next page
103
Chapter 5. The OPERA 30-day prediction model
Table 5.1 – Continued from previous page
All Re-admitted No events Compare
or died within with and
in 30 days 30 days w/o events
Heart Rate, BPM 1067 88 [72−108] 84 [70−106] 89 [73−108] <0.1





Diastolic BP, mmHg 1083 75 [63 − 86] 70 [60 − 82] 76 [64 − 87] <0.001
Sinus Rhythm, % 1088 446 (41%) 84 (35%) 362 (43%) <0.05
Weight, kg 987 82 [69 − 97] 79 [69 − 94] 82 [69 − 99] 0.19
BMI, kg/m2 806 29 [25 − 34] 29 [25 − 34] 29 [25 − 34] 0.53
Medication at admission
Total pill count 969 9 [5 − 13] 10 [6 − 14] 8 [5 − 12] <0.01
HF related symptoms at admission
NYHA(**): Class I or II, % 1052 81 (8%) 16 (7%) 65 (8%) <0.01
NYHA(**): Class III, % 651 (62%) 126 (54%) 525 (64%)
NYHA(**): Class IV, % 320 (30%) 91 (39%) 229 (28%)
Co-morbidities
CCI score: 1094
≤ 1, % 235 (22%) 53 (22%) 182 (22%) 0.15
2, % 199 (18%) 36 (15%) 163 (19%)
3, % 187 (17%) 40 (16%) 147 (17%)
4, % 149 (14%) 30 (12%) 119 (14%)
≥ 5, % 324 (30%) 87 (35%) 237 (28%)
Diabetes, % 1094 380 (39%) 74 (35%) 306 (40%) 0.27
COPD, % 1094 188 (17%) 49 (20%) 139 (16%) 0.23
HF symptoms and vital signs at discharge
Length of stay, days 1094 10 [6 - 17] 12 [7 − 21] 10 [6 − 16] <0.01
Weight, kg 693 77 [65 − 91] 75 [64 − 88] 78 [66 − 92] 0.13
NYHA: Class I or II, % 907 743 (82%) 134 (71%) 609 (85%) <0.001
NYHA: Class III, % 143 (16%) 45 (24%) 98 (14%)
NYHA: Class IV, % 21 (2%) 10 (5%) 11 (2%)
Dyspnoea at rest, % 932 60 (6%) 22 (11%) 38 (5%) <0.001
Left ventricular 920 0.30
Continued on next page
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Table 5.1 – Continued from previous page
All Re-admitted No events Compare
or died within with and
in 30 days 30 days w/o events
systolic dysfunction
-None-trivial 254 (28%) 193 (27%) 61 (31%)
-Mild-to-moderate 154 (17%) 27 (14%) 127 (18%)
-Moderate-to-severe 512 (56%) 111 (56%) 401 (56%)
Lab values at discharge
NT-proBNP, pg/mL 905 4468 6121 4100 <0.01
[1895−9889] [2013−12110] [1832−9210]
Urea, mmol/l 1087 9 [7 − 14] 11 [8 − 16] 9 [6− 13] <0.001
Creatinine, µmol/l 1085 105[83−140] 119[91−156] 102[82−136] <0.001
Medication at discharge
Total daily pill count 1044 12 [9 −16] 12 [9− 17] 12 [9 − 16] <0.05
Prior hospitalization
≥ 2 EM in prior 6 month,
%
1094 143 (13%) 46 (19%) 97 (11%) <0.01
≥ 1 EM in prior 1 month,
%
1094 189 (17%) 61 (25%) 128 (15%) <0.001
Social status/support
Reported good or excel-
lent support from fam-
ily,%
1094 451 (41%) 87 (35%) 364 (43%) <0.05
Living alone, % 962 349 (36%) 83 (41%) 266 (35%) 0.16
Married, % 1094 531 (49%) 102 (42%) 429 (51%) <0.05
Retired, % 912 783 (86%) 176 (92%) 607 (84%) <0.01
Mood and cognitive function
Depression, HADS 391 <0.05
-None, % 257 (66%) 43 (61%) 214 (67%)
-Mild, % 78 (20%) 11 (16%) 67 (21%)
-Moderate-to-severe, % 56 (14%) 17 (24%) 39 (12%)
Anxiety, HADS 384 0.7
-None, % 232 (60%) 44 (64%) 188 (60%)
Continued on next page
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Table 5.1 – Continued from previous page
All Re-admitted No events Compare
or died within with and
in 30 days 30 days w/o events
-Mild, % 87 (23%) 13 (19%) 74 (24%)
-Moderate-to-severe, % 65 (17%) 12 (17%) 53 (17%)
GPCOG score ≤ 4 399 29 (7%) 8 (10%) 21 (7%) 0.44
Frailty and mobility
Get up and go test: 781 284 (36%) 52 (32%) 232 (38%) 0.46
able or willing to partici-
pate, %
Time for get up 295 9 [6 − 15] 12 [8− 20] 8 [6 − 14] <0.01
and go test, sec
Having trouble 879 213 (24%) 57 (31%) 156 (23%) <0.05
bathing or dressing, %
Outcomes
30-day unplanned 1094 213 (19%) - - -
re-admission, %
30-day CV unplanned 1094 163 (15%) - - -
re-admission, %
30-day HF unplanned 1094 109 (10%) - - -
re-admission, %
30-day mortality, % 1094 60 (5%) - - -
NYHA, New York heart association; CCI, Charlson comorbidity index; HADS, hospital
anxiety and depression scale; GPCOG, general practitioner assessment of cognition
(*) 0.1 level of significance
(**) worst during the last 7-days
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51 died in hospital
Univariable analysis
On univariable analysis (Table 5.2), patients who were re-admitted or died were on
average older, had higher daily pill counts, worse NYHA class at admission and dis-
charge, worse renal function, and were more likely to have had recent and/or multiple
hospitalizations. They were also more likely to have evidence of physical frailty, prob-
lems with bathing and dressing, moderate-to-severe depression and cognitive impair-
ment. They were less likely to be married and more likely to be single.
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TABLE 5.2: Univariable analysis of the imputed dataset (all subjects included using
multiple imputation) for 30-day unplanned re-admission or mortality
N OR 95% CI
Age, years (*) 0 1.21 1.07 – 1.37
Women, yes 0 1.06 0.79 – 1.41
Heart Rate at admission, BPM (*) 27 0.95 0.90 – 1.00
Systolic BP at admission, mmHg (*) 11 0.94 0.88 – 0.99
Diastolic BP at admission, mmHg (*) 11 0.84 0.77 – 0.91
Weight at admission, kg 107 0.99 0.99 – 1.00
BMI at admission, kg/m2 288 0.99 0.97 – 1.01
Sinus Rhythm at admission, yes 6 0.70 0.52 – 0.94
Total pill count at admission 125 1.05 1.02 – 1.07
NYHA Class IV at admission, yes (**) 42 1.70 1.26 – 2.28
CCI, score 0 1.04 0.98 – 1.10
Diabetes, yes 0 0.79 0.58 – 1.07
COPD, yes 0 1.27 0.88 – 1.81
Length of stay, (*) 0 1.15 1.04 – 1.27
Weight at discharge, kg 401 0.99 0.99 – 1.00
NYHA class III/IV at discharge, yes 187 2.44 1.76 – 3.37
Dyspnoea at rest at discharge, yes 162 2.97 1.83 – 4.80
Moderate-to-severe LVSD, yes 174 1.01 0.73 – 1.38
NT-proBNP at discharge pg/mL (log) 189 1.22 1.08 – 1.37
Urea at discharge, mmol/l (log) 7 1.99 1.54 – 2.58
Creatinine at discharge, micromol/l (log) 9 1.93 1.37 – 2.72
Total daily pill count at discharge 50 1.03 1.01 – 1.05
Number of prior EM hospitalizations in 6 months 0 1.36 1.19 – 1.56
Prior EM in 1 month, yes 0 1.85 1.31 – 2.61
Reported good or excellent support from family, yes 0 0.73 0.54 – 0.97
Living alone, yes 132 1.36 1.02 – 1.82
Married, yes 0 0.69 0.52 – 0.92
Retired, yes 182 1.43 0.95 – 2.24
Depression, HADS 703
- None-to-mild, yes 1 -
Continued on next page
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Table 5.2 – Continued from previous page
N OR 95% CI
- Moderate-to-severe, yes 1.65 1.13 – 2.39
Anxiety, HADS 710
- None-to-mild, yes 1 -
- Moderate-to-severe, yes 1.18 0.81 – 1.70
Cognitive impairment GPCOG score ≥4, yes 695 1.83 1.18 – 2.80
Physical frailty, yes 249 1.77 1.13 – 2.88
N, number of imputed data points; OR, odds ratio; CI, confidence interval; LVSD, left ventricular
systolic dysfunction; NYHA, New York heart association; CCI, Charlson co-morbidity index;
EM, emergency; HADS, hospital anxiety and depression scale; GPCOG, general practitioner
assessment of cognition
(*)10 unit increase
(**) worst during the last 7-days
Multivariable analysis
In the reference clinical model, the following variables were associated with a worse
outcome: not being in sinus rhythm, a higher daily pill count, worse NYHA class, dys-
pnoea at rest, higher serum urea and plasma NT-proBNP at discharge, longer length
of hospital-stay and more emergency hospitalizations in the previous 6 months. Addi-
tional predictors included in the extended model were: not being married, poor family
support and being physically frail.
Data were missing for 20% of the patients for more than one of the variables included
in this model (Table 5.3). Analyses using a dataset of 572 patients for whom data were
complete showed similar results as imputed datasets (Appendix A tables 5.5 and 5.6).
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TABLE 5.3: Multivariable models predicting 30-day unplanned re-admission or mor-
tality in 1094 patients; reference model includes clinical characteristics; extended
model adds physical frailty and social predictors
Reference model Extended model
Variables N OR (95% CI) OR (95% CI)
Number of daily pills at admission 125 1.03 (1.00 – 1.06) 1.03 (1.00 – 1.06)
Sinus rhythm 6 0.77 (0.56 – 1.05) 0.77 (0.57 – 1.06)
Urea, mmol/l (log) at discharge 7 1.57 (1.19 – 2.07) 1.61 (1.22 – 2.13)
NT-proBNP pg/mL (log) at discharge 189 1.09 (0.96 – 1.24) 1.07 (0.94 – 1.21)
NYHA class at discharge, 1-class increase 187 1.47 (1.14 – 1.90) 1.40 (1.08 – 1.82)
Dyspnoea at rest at discharge 161 1.50 (0.86 – 2.63) 1.72 (0.98 – 3.04)
Length of stay (10-day increase) 0 1.08 (0.97 – 1.19) 1.07 (0.96 – 1.20)
Number of prior EM hospitalizations 0 1.27 (1.10 – 1.45) 1.26 (1.10 – 1.45)
in 6 months
Physical frailty 250 1.21 (0.73 – 2.00)
Married 0 0.72 (0.53 – 0.97)
Reported good or excellent 0 0.74 (0.53 – 1.02)
support from family
AUC [95% CI] 0.68 [0.64 – 0.72] 0.70 [0.66 – 0.74]
(Bootstrap optimism-corrected AUC) (0.66) (0.67)
N, imputed data; NYHA, New York heart association.
Model performance
The reference clinical model had an area under the curve in ROC analysis of 0.68 [95%
CI 0.64 – 0.72] in discriminating between patients who did or did not experience the
primary outcome of all-cause unplanned re-admissions or death within 30 days. The
extended model including physical frailty and social factors increased the AUC to 0.70
[95% 0.66 – 0.74]. Internal validation of the models by bootstrap provided a corrected
AUC of 0.66 for the clinical model and 0.67 for the extended model, respectively.
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The extended model for re-admission only or mortality only had AUC of 0.67 and 0.83,
with internally validated estimates of 0.65 and 0.80, respectively (Table 5.4).
TABLE 5.4: Discrimination of reference clinical models and extended models for com-
posite and single outcomes among HF patients; reported as AUC [95% CI] (Bootstrap
optimism-corrected AUC)
30-day composite 30-day unplanned 30-day mortality
outcome re-admission
Reference model 0.68 [95% CI 0.64 – 0.72] 0.65 [0.61 – 0.69] 0.81 [0.76 – 0.87]
(0.66) (0.63) (0.79)
Extended model 0.70 [95% CI 0.66 – 0.74] 0.67 [0.63 – 0.71] 0.83 [0.77 – 0.88]
(0.67) (0.65) (0.80)
Incremental p-value <0.05 <0.05 0.27
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DISCUSSION
This study demonstrates the high prevalence of diverse aspects of frailty amongst pa-
tients admitted to hospital with worsening heart failure and their contribution to 30-
day outcomes. Most clinical trials and registries of patients hospitalized for heart fail-
ure collect only clinical information thought useful by cardiologists. Only a few have
collected data on other aspects of patient well-being and very few have investigated
the importance of cognitive function or social support. Our study suggests that assess-
ing diverse aspects of frailty, physical or social, improves prediction of near-term out-
comes. However, prediction remains difficult especially for re-hospitalization. Future
analyses will determine whether different aspects of frailty also predict longer-term
outcomes.
We found that 1 in 5 patients hospitalized for heart failure will have an unplanned
re-admission and 1 in 20 patients will die within 30 days of discharge. Not all events
were related to HF and not all would have been preventable, although this was not
evaluated for individual cases. Clinical trials focusing on treatments to improve car-
diac function for patients with decompensated heart failure have met with a remark-
able lack of success. This failure may be because one or more aspects of frailty, which
will not respond to short-term pharmacological interventions, are key determinants of
outcome. Indeed, measures of frailty, in particular physical and social, were strongly
associated with outcome in our registry. In conventional prognostic models, age is
usually a strong predictor of outcome, probably because of its association with mul-
tiple aspects of frailty and co-morbidity rather than merely chronological age. In the
present multivariable analysis, age was not an independent predictor of outcome per-
haps because chronological age is just a surrogate measure for frailty.
Published prognostic models focusing on clinical variables alone for the prediction
of short-term outcome have reported relatively poor discrimination, especially for re-
hospitalisation, which is consistent with our findings [5, 6, 7]. The performance of our
model is amongst the highest for the composite end-point of all-cause re-hospitalisation
or mortality within the first few weeks after discharge [7]; although the discrimination
for re-hospitalisation is similar to other published models, we achieved a high dis-
crimination for predicting mortality. Our model would be relatively simple to apply
to routine care provided information from nursing as well as medical records.
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Financial penalties are imposed on hospitals in some countries if a patient is re-admitted
within 30 days, and therefore models predicting short-term events, especially if they
are preventable, could be used to improve the quality of care. A high rate of re-
admission may reflect a poor quality service that simply fails to prevent events. A
high rate of re-admission may also occur in a high-quality service that only admits pa-
tients with advanced disease who cannot be managed in the community: such patients
are consequently at a high risk of further events. Models can be used to compare pre-
dicted and actual outcome in different hospitals, taking case-mix, disease severity and
diverse aspects of frailty into account. However, even with our extended model, vari-
ables shown in previous studies to be related to prognosis were not included in our fi-
nal model. This may reflect inaccurate methods of collecting some data or the inherent
unpredictability of some events. Our findings confirm prior evidence of the difficulty
of predicting readmission. Further research is needed to explore the added value of
other factors, such as evidence of decongestion, early scheduled post-discharge clini-
cal evaluation or therapy at discharge.
It is important to note that many patients were sufficiently incapacitated that they
felt unable to undertake tests of physical frailty, complete questionnaires manually or
even provide consent to participate in a registry. Indicative of that is that only 278
patients in our cohort were able or willing to perform the timed “get up and go” test.
Accordingly, our study underestimates the true burden of frailty amongst patients
admitted to hospital with heart failure, which might only be properly assessed by
clinical audits that do not require individual patient consent.
Physical frailty will be influenced by the severity of heart failure, co-morbidities and
pre-morbid lifestyle and strongly associated with age. An extreme form of frailty is
cardiac cachexia, leading to a loss of both fat and muscle mass [24]. Studies consis-
tently show that patients with heart failure who have a high BMI (in the range of 30 to
35) have a better prognosis [25], although whether this reflects milder cardiac disease
or is actually protective is controversial. There is a growing interest in both sarcopae-
nia and physical frailty as therapeutic targets [26]. Studies of exercise training have
suggested improvements in quality of life but no clear reduction in hospitalization or
mortality [27]. Studies of anabolic agents have been of modest size and clinical benefit
is again uncertain [28].
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Poor social support may be considered another aspect of frailty [29]. A patient receiv-
ing support from their family may be less likely to be admitted to hospital. Strong
social bonds may also be an important motivation for self-help. They provide a net-
work that reinforces advice on life-style and medication adherence and ensure that
patients are well nourished. Companionship itself might improve prognosis, giving
patients “something to live for” [30].
Two other aspects of frailty can be emotional frailty (anxiety or depression) or mental
(cognitive dysfunction). Our univariable results suggest that depression and cognitive
dysfunction should not be overlooked either. Several studies suggest a strong link be-
tween depression, functional status [31] and outcome [32, 33]. Many patients with
heart failure appear to recover from depression if their condition is stabilized, sug-
gesting it might often be a reaction to ‘bad news’, while antidepressants have not yet
been shown to reduce re-hospitalization or death [28]. Mental frailty, in other words
cognitive dysfunction, is a growing concern amongst older patients and therefore it
is no surprise that it should be common in patients with heart failure [34]. There are
many reasons why cognitive dysfunction should be associated with a worse outcome.
It is associated with older age, co-morbidity and physical frailty.
Study limitations. One important limitation of our model is missing data. We addressed
this by using multiple imputation and confirmed the robustness of our approach by
repeating the analysis only on un-imputed data, which gave similar results. Another
limitation is that the model was only internally validated. Further external validation
for other hospitals in the UK and in other countries with different provision and orga-
nization of health-care is required. Some of our data-collection methods, for instance
the HADS questionnaire, have been developed primarily for research and have not
been extensively tested in routine practice for patients with heart failure. Question-
naires were only administered once; changes are likely to have occurred during or
after hospitalization. Physical frailty was assessed by the timed “get up and go” test
and by reported difficulties in bathing and dressing. These describe functional status
and disability, which are part of a broader conception of “frailty”, which, however,
does include other elements, such as mental frailty [35]. The limited number of pa-
tients willing or able to perform the get up and go test limits the wider applicability
of the frailty test. Finally, we restricted our analysis to 30 day outcome, while longer
term patterns are also relevant.
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Conclusions. Measures of frailty and social support improve the prediction of 30-day
unplanned readmission or death to a modest extent compared to models including
only conventional clinical risk predictors. However, prediction of events in the short-
term, especially re-hospitalisation, remains difficult. Which aspects of frailty are most
important and whether interventions to reduce frailty can improve outcome, requires
more research.
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APPENDIX A: COMPLETE CASES ANALYSIS
TABLE 5.5: Univariable analysis of original dataset (complete cases analysis) for 30
day unplanned re-admission or mortality; Only subjects with available data
No. OR 95% CI
Age, years (*) 1094 1.21 1.07 – 1.37
Women, yes 1094 1.06 0.79 – 1.41
Heart Rate at admission, BPM (*) 1067 0.95 0.90 – 1.00
Systolic BP at admission, mmHg (*) 1083 0.94 0.89 – 1.00
Diastolic BP at admission, mmHg (*) 1083 0.83 0.76 – 0.91
Weight at admission, kg 987 0.99 0.99 – 1.00
BMI at admission, kg/m2 806 0.99 0.97 – 1.01
Sinus Rhythm at admission, yes 1088 0.71 0.53 – 0.95
Total pill count at admission 969 1.04 1.02 – 1.07
NYHA at admission: Class IV, yes (**) 1052 1.65 1.22 – 2.24
CCI, score 1094 1.04 0.98 – 1.10
Diabetes, yes 1094 0.78 0.57 – 1.06
COPD, yes 1094 1.27 0.88 – 1.81
Length of stay, (*) 1094 1.15 1.04 – 1.27
Weight at discharge, kg 693 0.99 0.98 – 1.00
NYHA class III/IV at discharge, yes 907 2.29 1.57 – 3.32
Dyspnoea at rest at discharge, yes 932 2.37 1.35 – 4.08
Moderate-to-severe left ventricular systolic dysfunction, yes 920 1.01 0.73 – 1.38
NT-proBNP at discharge pg/mL (log) 905 1.20 1.05 – 1.37
Urea at discharge, mmol/l (log) 1087 1.96 1.51 – 2.55
Creatinine at discharge, micromol/l (log) 1085 1.95 1.38 – 2.75
Total daily pill count at discharge 1044 1.03 1.01 – 1.05
Prior EM in 1 month, yes 1094 1.85 1.31 – 2.61
Number of prior EM hospitalizations in 6months 1094 1.36 1.19 – 1.56
Reported good or excellent support from family, yes 1094 0.73 0.54 – 0.97
Living alone, yes 962 1.27 0.92 – 1.74
Married, yes 1094 0.69 0.52 – 0.92
Retired, yes 912 2.20 1.29 – 4.02
Depression, HADS 391
Continued on next page
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Table 5.5 – Continued from previous page
No. OR 95% CI
- None-to-mild, yes 1 -
- Moderate-to-severe, yes 2.27 1.17– 4.25
Anxiety, HADS 384
- None-to-mild, yes 1 -
- Moderate-to-severe, yes 1.04 0.50 – 2.02
Cognitive impairment GPCOG score ≤ 4, yes 399 1.55 0.62 – 3.52
Physical frailty, yes 845 2.05 1.21 – 3.69
NYHA, New York Heart Association; CCI, Charlson co-morbidity index; HADS, hospital
anxiety and depression scale; GPCOG, general practitioner assessment of cognition
(*)10 unit decrease; (**) worst during the last 7 days
TABLE 5.6: Multivariable models developed on n=572 complete cases predicting 30-
day unplanned re-admission or mortality; reference model includes clinical character-
istics; extended model adds physical frailty and social predictors
Reference model Extended model
Variables OR (95% CI) OR (95% CI)
Number of daily pills at admission 1.04 (1.00 – 1.07) 1.04 (1.00 – 1.08)
Sinus rhythm 0.64 (0.41 – 0.99) 0.63 (0.40 – 0.98)
Urea, mmol/l (log) at discharge 1.63 (1.10 – 2.42) 1.61 (1.08 – 2.40)
NT-proBNP pg/mL (log) at discharge 0.97 (0.81 – 1.16) 0.95 (0.80 – 1.14)
NYHA class at discharge, 1-class increase 1.45 (1.01 – 2.42) 1.39 (0.96 – 2.01)
Dyspnoea at rest at discharge 2.06 (0.99 – 4.29) 2.27 (1.07 – 4.81)
Length of stay (10-day increase) 1.04 (0.88 – 1.23) 1.03 (0.86 – 1.23)
Prior EM hospitalizations in 6months 1.28 (1.07 – 1.53) 1.26 (1.05 – 1.51)
Physical frailty 1.37 (0.69 – 2.69)
Married 0.64 (0.41 – 0.99)
Reported good or excellent 0.92 (0.59 – 1.43)
support from family
AUC (Bootstrap optimism-corrected AUC) 0.69 (0.67) 0.71 (0.68)
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Chapter 6. External validation of the OPERA model
ABSTRACT
Aims: Chronic disease patients are at high risk of adverse events such as unplanned
readmission or mortality. The aim of this study is to evaluate the generalizability of
the previously developed OPERA-heart failure (HF) model for outcome prediction in
another geography.
Methods and results: SAPHIRE is an observational prospective cohort study, consist-
ing of patients hospitalized for HF or chronic obstructive pulmonary disease (COPD)
in a tertiary care hospital in St. Louis, Missouri. Among 513 study participants diag-
nosed with HF, 72 (14%) had an unplanned all-cause readmission and 27 (5%) died
within 30 days after discharge from the hospital. The risk prediction model based on
the OPERA-HF study had an area under the receiver operating characteristic curve
(AUC) of 0.70. When applied on SAPHIRE, the model showed similar discrimina-
tion (AUC 0.70 [95% confidence interval 0.65 – 0.76]) and provided accurate risk es-
timations (predicted 17%, observed 18%). By refitting the model to the SAPHIRE HF
cohort, the performance was improved further (AUC 0.72 [95% CI 0.66 – 0.78]).
Conclusion: External validation demonstrated good calibration of the OPERA-HF
model. Discrimination of those at low risk versus those at high risk remains modest,
even upon refitting the model, implying a need for better predictors of poor outcome
within 30 days after discharge.
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INTRODUCTION
Nearly half of the adults in the US have at least one chronic condition, contributing to
over 75% of hospital days, office visits, home health care and prescription drugs, and
thus more than 80% of the total healthcare costs [1]. Re-admissions account for more
than 30% of annual US healthcare expenditures [2]. This led to the Hospital Readmis-
sion Reduction Program, which was implemented by the Centers for Medicare and
Medicaid Services (CMS) in 2012. This program imposes financial penalties on hos-
pitals if their 30-day risk-adjusted readmission rates exceed national averages after
an index hospitalization for several key discharge diagnoses, including heart failure
(HF) [3]. Approximately 25% of the 1 million HF patients hospitalized annually in US
are readmitted within 30 days of discharge [4, 5]. The multiple re-admissions of HF
patients often reflect a substantial impairment in the patient’s quality of life and are
associated with increased mortality and high healthcare costs [6, 7].
Risk models have been developed that examine reasons of readmission and mortality
in HF patients. However, these often are only internally validated and not tested in dif-
ferent geographies or healthcare systems. Only a few models have been externally val-
idated, showing a poor performance [8]. Models predicting 30-day unplanned read-
mission tend to perform worse than models predicting mortality, all cause admissions
or outcomes in longer time spans [8, 9]. 30-day readmission models usually include
clinical factors and ignore psychosocial, healthcare utilization or patient frailty.
The OPERA-HF study included 1094 HF patients from the UK, where 213 (19%) expe-
rienced an unplanned readmission and 60 (5%) died within 30 days of discharge from
index admission. A 30-day unplanned readmission or mortality prediction model was
developed that included clinical factors (increasing daily pill counts at admission, be-
ing in sinus rhythm at admission, dyspnea at rest, NYHA class III or IV, increasing
urea and NT-proBNP at discharge, length of stay in the hospital and number of prior
emergency hospitalizations in 6 months) combined with physical frailty, not being
married, and not perceiving family support. The aim of this analysis is to validate the
generalizability of the OPERA-HF model in another geography and healthcare system.
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METHODS
Study design
The SAPHIRE-HF/COPD study is a prospective cohort study consisting of patients
aged 18 years and older who were admitted to Mercy Hospital in St. Louis, Mis-
souri for HF and/or COPD. The aim of the study is to identify contributing factors
to adverse outcomes for HF and COPD patients, to evaluate the additional value of
non-clinical factors and to analyze the validity of prediction models. All participants
had to provide written informed consent and meet all of the following inclusion crite-
ria: physically and mentally capable to cooperate based on clinical judgement of the
care manager nurse, understand and speak the English language and willing to fill
out the questionnaires during their hospitalization. Patients were excluded for any of
the following reasons: observation unit admission only, part of another research study
involving novel medications or devices, illicit drug use, or designated for transport to
hospice at discharge. The study started in October 2014 and was approved by Mercy
Health’s Institutional Review Board. For the purposes of this report we focus only on
the HF cohort of the study.
Data collection
Several variables known to be potential risk factors for adverse events in HF patients
were collected by research nurses using automated electronic medical record (EMR)
extractions and manual chart reviews. Information on depression and anxiety was
also collected from the EMRs with no additional assessment conducted. Additional
questionnaires were administered to the patients once during hospitalization about
general demographics, socioeconomic issues, prior hospitalizations, functional limita-
tions and ability to self-care.
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Physical frailty
For frailty, a two-fold assessment was applied. Patients were asked to respond to a
question about having trouble bathing or dressing and then they were asked to un-
dergo the timed ‘get up and go’ test [10]. The timed ‘get up and go’ requires patients
to stand up from a chair, walk a short distance (3 m) using any walking aids if needed,
turn around, return, and sit down again. A time of less than 10 seconds to complete
this task is considered normal for a healthy individual whereas a time of more than 20
seconds is considered abnormal. Patients who reported trouble with bathing or dress-
ing, or patients who were not able to complete the ‘get up and go’ test in less than 20
seconds were defined as frail.
Endpoints
The primary study end-point was unplanned readmission. Mortality within 30 days of
discharge from index admission was a secondary outcome. Outcomes were collected
through EMR reviews of hospital encounters and national death records. Readmis-
sions to healthcare systems other than Mercy Health may be missed using this method,
though patients generally stay within the system for any follow-up care.
OPERA Model
The OPERA-HF study was an observational prospective study consisting of patients
hospitalized for HF in Hull, UK. The OPERA model [11] is a logistic regression model
developed based on the OPERA-HF cohort for prediction of 30-day unplanned all-
cause readmissions or mortality. The predictors included in the model are a combi-
nation of clinical variables (increasing daily pill counts at admission, sinus rhythm at
admission, dyspnea at rest, NYHA class III or IV and increasing urea and NT-proBNP
at discharge), hospital utilization (length of stay in the hospital and number of prior
emergency hospitalizations in 6 months), not being married, not perceiving family
support and being physically frail. This combination demonstrated a discrimination
(area under the receiver operating characteristic curve, AUC) of 0.70 [95% CI 0.66 –
0.74].
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Statistical analysis
Data were analyzed from patients who participated in the study between October 2014
and January 2017. Baseline characteristics were compared between the HF cohort from
this study and the OPERA-HF study sample using the χ2 test for binary or categorical
variables, and the Kruskal-Wallis test for continuous variables.
Univariable logistic regression analysis was applied to relate patient characteristics
to unplanned readmission or mortality within 30 days after discharge. Odds ratios
(ORs) were calculated with 95% confidence intervals (CIs). The results were compared
with the univariable results from the OPERA-HF study. The OPERA model was then
applied to the HF patients in this study. Multiple Imputation (MI) was used to impute
missing data. MI technique requires three steps: imputation, analysis and pooling.
Each missing value was imputed five times following the predictive mean matching
method, thus producing five imputed data sets; each one of these five imputed data
sets was then analyzed and the results were pooled into one final analysis following
Rubin’s method [12, 13]. For predictors not collected at all in our study, we used the
mean values of the original data distribution when applying the model.
Discrimination and calibration were used to assess the external validity of the model
[14, 15]. Discrimination refers to the ability to distinguish patients who will be read-
mitted from those who will not, and was quantified by the AUC. An AUC of 0.5 in-
dicates no discriminative ability at all while an AUC of 1 indicates perfect discrimi-
nation [16, 17]. Calibration describes the agreement between observed and predicted
outcomes. Calibration was assessed visually with a calibration plot. Groups of pa-
tients were created based on their predicted risk (deciles), which was plotted against
the observed event rate for each decile. A majority of plotted risks being below the
x=y line indicates overfitting, while a perfect model would coincide with the x=y line.
Calibration-in-the-large was assessed by using the logit of the model predictions as
input to a logistic regression model, which allows for inspection of the intercept as
measure of structural overestimation of underestimation [14].
The model was further refitted to the SAPHIRE-HF patients and internally validated
by a bootstrapping procedure, by sampling with replacement for 200 iterations [16, 18].
Bootstrapping was performed within each imputed data set. We planned to combine
both cohorts and refit the model to derive a final model optimized for both sites.
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All analyses were conducted using R 3.3.3 statistical software (The R Foundation for
Statistical Computing, Vienna, Austria).
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RESULTS
Baseline characteristics of the study population
Of the 1571 patients approached, 644 consented and enrolled to the study (460 with
a diagnosis of HF, 131 with a diagnosis of COPD, 53 with both diagnoses at enroll-
ment as indicated by the hospital EMR, Figure 6.1). Thus, 513 patients had a primary
or secondary diagnosis of HF and were included for analysis (Table 6.1). Participants
had a median age of 73 years, 52% were women, 69% retired, 49% married, 34% had
Left Ventricular Ejection Fraction (LVEF) ≤ 40% at discharge and median NT-proBNP
was 3035 pg/mL at discharge. Their median length of stay in the hospital was 4.8
days and their Body Mass Index (BMI) was relatively high (median 31 kg/m2). De-
pression and anxiety was prevalent in 13% and 11% of the sample, respectively. In the
questionnaires, 13% reported trouble with bathing or dressing. Unplanned, all-cause
readmission occurred in 72 (14%) participants within 30 days from index discharge
while 27 (5%) died within the first 30 days after discharge.
Relative to OPERA-HF patients, SAPHIRE-HF patients were younger and more often
female (Table 6.1). OPERA-HF patients were more likely complex HF patients with
more comorbidities, significantly lower BMI, had longer hospital stays and higher
average NT-proBNP value at discharge in comparison to the SAPHIRE-HF cohort.
OPERA-HF patients also were less often in sinus rhythm and were more likely to ex-
perience a readmission.
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FIGURE 6.1: Consort diagram
1571 patients screened in total: 1191
HF, 317 COPD, 63 COPD and HF
668 ineligible: 222 mental capacity,
10 illicit drug use, 22 language bar-
rier, 24 discharge to hospice, 9 other
drug/device study, 381 refused study intro
903 eligible 156 refused participation, 90 missed
657 completed informed consent 13 terminated participation or du-plicate enrollement or no follow-up
644 enrolled to SAPHIRE-HF/COPD:
460 HF, 131 COPD, 53 HF and COPD
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TABLE 6.1: Comparison of baseline patient characteristics and outcomes of SAPHIRE-
HF with OPERA-HF.
SAPHIRE-HF OPERA-HF
(N= 513) (N= 1094)
Characteristics N Summary* N Summary* p-value**
Demographics
Age (years), median [IQR] 513 73 [62 – 82] 1094 77 [68 – 83] <0.001
Women, n (%) 513 265 (52 %) 1094 433 (40 %) <0.001
Vital signs at hospital admission and other measurements
Systolic BP (mmHg), median
[IQR]
NA NA 1083 129 [115–146] NA
Diastolic BP (mmHg), median
[IQR]
NA NA 1083 75 [63 – 86] NA
Sinus Rhythm, n (%) 477 245 (51 %) 1088 446 (41 %) <0.001
Medication at admission
Total pill count, median [IQR] 512 7.5 [7.5 – 13] 969 9 [5 – 13] <0.05
History Comorbidities
Diabetes, n (%) 498 132 (27 %) 1094 380 (39 %) <0.01
COPD, n (%) 498 76 (15 %) 1094 188 (17 %) 0.42
Cancer, n (%) 498 38 (8%) 1094 122 (11 %) <0.05
HF symptoms and vital signs at discharge
Length of stay (days), median
[IQR]
513 4.8 [3.1 – 7.7] 1094 10.1 [6.0 – 17.0] <0.001
BMI (kg/m2), median [IQR] 512 31 [26 – 39] 587 27 [23 – 32] <0.001
NYHA: Class III/ IV, n (%) NA NA 907 164 (18 %) NA
LVEF ≤ 40 at discharge, n (%) 488 166 (34 %) 920 512 (56 %) <0.001
Lab values at discharge
NT-proBNP (pg/ml), median
[IQR]
480 3035[1411–7117] 905 4468[1895-9889] <0.001
Urea (mmol/l), median [IQR] 513 9 [7 – 14] 1087 9 [7 – 14] 0.22
Creatinine (micmol/l), median
[IQR]
513 111 [84 – 154] 1085 105 [83 – 140] <0.05
Bilirubin (mg/dl), median [IQR] 475 0.5 [0.4 - 0.9] 1085 0.9 [0.7 – 1.2] <0.001
Prior hospitalization
Continued on next page
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Table 6.1 – Continued from previous page
SAPHIRE-HF OPERA-HF
(N= 513) (N= 1094)
Characteristics N Summary* N Summary* p-value**
>2 prior EM in 6months, n (%) 513 18 (4 %) 1094 55 (5 %) 0.21
Social status/support
Living alone, n (%) NA NA 938 324 (35 %) NA
Married, n (%) 513 250 (49 %) 1094 531 (49 %) 0.98
Retired, n (%) 512 353 (69 %) 912 783 (86 %) <0.001
Mood and cognitive function
Depression, n (%)*** 513 67 (13 %) 391 56 (14 %) 0.72
Anxiety, n (%)*** 513 58 (11 %) 384 65 (17 %) <0.05
Cognitive impairment, n (%) NA NA 399 29 (7 %) NA
Frailty and mobility
Time for get up and go 207 17 [11 – 31] 295 9 [6 - 15] <0.001
test (sec), median [IQR]
Having trouble bathing 512 64 (13 %) 879 213 (24 %) <0.001
or dressing, n (%)
Outcomes
30-day unplanned 513 72 (14 %) 1094 213 (19 %) <0.05
re-admission, n (%)
30-day CV unplanned 513 19 (4 %) 1094 163 (15 %) <0.001
re-admission, n (%)
30-day HF unplanned 513 18 (4 %) 1094 109 (10 %) <0.001
re-admission, n (%)
30-day mortality, n (%) 513 27 (5 %) 1094 60 (5 %) 1
IQR, Interquartile range;N, available data; LVEF, left ventricular ejection fraction; NYHA, New York
Heart Association; EM, emergency.
(*) summaries are based on patients with available data;
(**) 0.1 level of significance;
(***) in SAPHIRE-HF depression and anxiety were extracted by EMRs, while in OPERA-HF
additional assessments were applied (by HADS questionnaires [19])
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SAPHIRE-HF prognostic effects
In the univariable analysis of the 513 SAPHIRE-HF patients (Table 6.2), older age,
longer length of stay in the hospital, higher urea and creatinine, history of one or more
prior emergency admission during the last 6 months, and the presence of frailty were
all associated with an increased risk of 30-day unplanned readmission or mortality.
The estimated univariable effects were similar between studies.
TABLE 6.2: Univariable analysis for 30-day unplanned re-admission or mortality
(SAPHIRE-HF, N = 513; OPERA-HF, N = 1094).
SAPHIRE-HF OPERA-HF
OR 95% CI OR 95% CI
Age, years (10-unit increase) 1.19 1.00 – 1.43 1.21 1.07 – 1.37
Women, yes 1.14 0.73 – 1.78 1.06 0.79 – 1.41
Sinus rhythm, yes 0.61 0.39 – 0.96 0.70 0.52 – 0.94
Total pill count at admission 1.03 0.99 – 1.07 1.05 1.02 – 1.07
Diabetes, yes 1.29 0.78 – 2.11 0.79 0.58 – 1.07
COPD, yes 0.82 0.41 – 1.53 1.27 0.88 – 1.81
Cancer, yes 0.82 0.30 – 1.86 1.14 0.73 – 1.75
Length of stay, 10-day increase 1.73 1.14 – 2.61 1.15 1.04 – 1.27
BMI at discharge, kg/m2 1.00 0.97 – 1.00 0.99 0.97 – 1.01
LVEF ≤40 at discharge, yes 0.93 0.57 – 1.49 1.01 0.73 – 1.38
NT-proBNP at discharge pg/ml (log) 1.24 1.05 – 1.48 1.22 1.08 – 1.37
Urea at discharge, mmol/l (log) 2.91 1.89 – 4.55 1.99 1.54 – 2.58
Creatinine at discharge, micmol/l (log) 1.92 1.23 – 2.99 1.93 1.37 – 2.72
Bilirubin at discharge, mg/dl (log) 1.32 0.92 – 1.88 1.12 0.83 – 1.56
Number of prior EM in 6months 1.32 1.05 – 1.64 1.36 1.19 – 1.56
Married, yes 0.86 0.55 – 1.35 0.69 0.52 – 0.92
Retired, yes 1.15 0.71 – 1.90 1.43 0.95 – 2.24
Depression, yes 1.63 0.87 – 2.93 1.65 1.13 – 2.39
Anxiety, yes 1.49 0.76 – 2.79 1.18 0.81 – 1.70
Physical frailty, yes 2.55 1.56 – 4.32 1.77 1.13 – 2.88
OR, Odds Ratio; CI, Confidence Interval; COPD, chronic obstructive pulmonary disease;
BMI, body mass index; LVEF, left ventricular ejection fraction; CV, cardiovascular;
EM, emergency.
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OPERA model validation
At external validation, the OPERA model showed a similar discrimination to the orig-
inal (AUC 0.70 [95% CI 0.65 – 0.76]) and good overall risk estimation (predicted 17%,
observed 18%, p = 0.44). The plotted risks being close to the x=y line confirm that the
probabilities of readmission were well estimated (Figure 6.2).
Multivariable analysis
Most effects of predictors were similar between cohorts. The effect of number of pre-
scribed pills at admission and social support were stronger in OPERA, while the effects
of higher urea and being frail were stronger in SAPHIRE (Table 6.3).
When refitting the model, we achieved a slightly higher performance of AUC 0.72
[95% CI 0.66 – 0.78] (corrected for optimism AUC 0.69).
When combining both cohorts, the effects of number of prescribed pills, urea, frailty
and prior events were strongest. The discriminatory performance remained similar
(AUC 0.71 [95% CI 0.68 – 0.74], with an optimism-corrected estimate of AUC=0.69)
(Table 6.3).
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FIGURE 6.2: Calibration plot for the external validation of the OPERA model on
SAPHIRE-HF data; the triangles indicate the observed frequencies by deciles of pre-
dicted probabilities with 95% confidence intervals (vertical lines); the distribution of
patients having vs not having an event is shown at the bottom of the graph
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TABLE 6.3: Multivariate analysis and discrimination of 30-day unplanned readmission
or mortality models.
OPERA Refitted model Combined model
(N = 1094) (N = 513) (N = 1607)
Variable OR (95 % CI) OR (95 % CI) OR (95 % CI)
Number of daily 1.03 (1.00 – 1.06) 1.01 (0.96 – 1.05) 1.02 (1.00 – 1.04)
pills at admission
Sinus rhythm 0.77 (0.57 – 1.06) 0.65 (0.40 – 1.06) 0.75 (0.58 – 0.97)
at admission
Urea, mmol/l (log) 1.61 (1.22 – 2.13) 2.45 (1.55 – 3.88) 1.74 (1.37 – 2.20)
at discharge
NT-proBNP pg/mL 1.07 (0.94 – 1.21) 1.02 (0.85 – 1.23) 1.07 (0.97 – 1.19)
(log) at discharge
NYHA class 1.40 (1.08 – 1.82) Not available 1.48 (1.19 – 1.85)
at discharge,
1-class increase
Dyspnea at rest 1.72 (0.98 – 3.04) Not available 1.37 (0.83 – 2.28)
at discharge
Length of stay, 1.07 (0.96 – 1.20) 1.37 (0.88 – 2.13) 1.07 (0.97 – 1.18)
10-days increase
Prior EM 1.26 (1.10 – 1.45) 1.22 (0.96 – 1.54) 1.24 (1.10 – 1.40)
hospitalizations
in 6months
Physical frailty 1.21 (0.73 – 2.00) 2.24 (1.31 – 3.84) 1.73 (1.20 – 2.49)
Married 0.72 (0.53 – 0.97) 1.05 (0.63 – 1.73) 0.79 (0.61 – 1.02)
Perceiving support 0.74 (0.53 – 1.02) 0.64 (0.36 – 1.14) 0.80 (0.62 – 1.04)
from family
Validation Original External Refitted Combined
validation
AUC 0.70 0.70 0.72 0.71
[95% CI] [0.66-0.74] [0.65 – 0.76] [0.66 – 0.78] [0.68 – 0.74]
(Bootstrap optimism (0.67) (0.69) (0.69)
corrected)
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DISCUSSION
In this study, we externally validated an existing predictive model for early readmis-
sion or mortality in HF patients. We found good performance with discrimination
similar to the original cohort and good calibration.
By comparing the two cohorts, we found that both studies had similar event rates and
similar mortality rates, while the early, unplanned readmission rates were different
between the US cohort (14%) and the UK cohort (19%). The difference in the readmis-
sion rate may partially be explained by the fact that in Hull all data were retrieved
from the single institution providing hospital care in the area, making readmission
elsewhere unlikely. On the other hand, in SAPHIRE there is a possibility of readmis-
sions occurring to institutions outside of the network and hence not being captured.
Other differences observed were that the US population was younger with less co-
morbidities. In spite of these differences and the differences in health care systems, we
observed similar effects in both studies in the univariable analysis. Increasing age, not
being in sinus rhythm, longer length of stay, increasing NT-proBNP, urea or creatinine,
more prior events or being frail were all related to an increase risk of poor outcome.
The OPERA model performed well when tested in this geography supporting trans-
portability of the model beyond one single site. By refitting the model in the external
validation cohort, we improved the performance slightly. As a model update, we com-
bined the cohorts and refitted the model on both such as to optimize the model for both
geographies. Further external validation of the combined model in other geographies
may assess the generalizability beyond the European and US settings considered so
far.
In this analysis we confirmed the hypothesis that a combination of clinical and non-
clinical variables provides better discrimination of the early outcomes compared to
the known, purely clinical, models from the literature [8]. In the refitted model we
achieved a significant improvement in the performance with a discrimination of AUC
of 0.72. Although this level of discrimination is modest, we achieved a higher AUC
than most HF models available in the literature [8, 20]. Predicting early readmissions
with high accuracy remains challenging because of the multidimensional root causes
of the events. Further research is needed to discover other predictors not yet studied
that may improve the discrimination.
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Frailty is an increasingly recognized factor affecting adverse outcomes in HF patients
[21, 22]. As suggested by our analysis, taking frailty into account can improve pre-
diction of outcomes following discharge from the hospital after an admission for HF.
Physical frailty should not be overlooked in discharge plans for HF patients. Interven-
tions to properly manage frail patients should be investigated that may improve the
outcomes. Studies of exercise training have suggested improvements in quality of life
but no clear reduction in hospitalization or mortality [23]. Studies of anabolic agents
have been of modest size and clinical benefit is as yet uncertain [24].
As an indication of ‘social frailty’, marital status and support from family, should also
not be overlooked. Our findings, suggest that a patient receiving support from their
family may be less likely to be re-admitted to hospital. Perceiving social support may
also be an important motivation for self-help for the patient [25]. Further research is
recommended for interventions targeted at patients with poor social support that may
improve their outcomes after discharge. One promising strategy is to send the patient
home with high touch points or services to help the patient manage him or herself and
stay out of the hospital.
An advantage of our model is that it is based on simple and easy to obtain variables
either directly from the EMRs or by simple additional assessments. The output of the
model is a risk score that is easily interpreted by clinicians. The simplicity of our model
makes it easy to use as part of routine care due to commonly available variables. It can
support the clinicians to optimize the post-discharge services provided to patients.
Further research on model implementation in clinical practice and validation in other
datasets is required.
Limitations. This study adds to the growing literature on predictors for HF early ad-
verse events, but some limitations should be mentioned. The definitions of the col-
lected data in SAPHIRE and methods of reporting were not identical to the OPERA-
HF data points. However, this may be expected when considering two very differ-
ent healthcare systems and geographies. Despite all these differences, discriminatory
performance and calibration were adequate, supporting the transportability of the
OPERA model. Missing data is a minor limitation in our study; we partially overcame
this issue by using multiple imputation. In addition, the validated questionnaires use
colloquial language that may not have been understood by patients from different
backgrounds.
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Conclusion. The OPERA model has good calibration in a different geography. Further
research on other potential predictors and evaluation of the OPERA model in clinical
practice is recommended.
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Chapter 7. General discussion
Heart failure (HF) patients have high hospitalization rates followed by high readmis-
sion rates with about 25% of them being readmitted within 30 days [1] leading to
worse quality of life for the patient [2] as well as high financial implications for the
health care systems [3]. Although clinical treatment is constantly being optimized [4],
further optimization is needed with respect to community care, social care or psy-
chological support provided to the patient. Identifying risk factors affecting adverse
events in HF patients is important for the patients and the care providers, since new
risk factors may lead to new methods to manage patients and optimize services. Tai-
lored treatment to the specific needs of the patient including non-medical services,
well-coordinated amongst multiple professional care disciplines could lead to better
outcomes.
The aim of this thesis was to expand our knowledge on risk factors affecting recurrent
readmissions or mortality in HF patients, develop a predictive model for early adverse
events by taking into account the added predictive value of non-clinical factors and
test the transferability of the model by externally validating it in a different geography.
The specific research questions are listed in Table 7.1 along with some of the main
findings.
TABLE 7.1: Research questions and findings
Research question Findings
What is the impact of Depression
depression and anxiety - Prevalence: 29%
on mortality in - Unadjusted effect: HR = 1.6; 95%CI 1.3 – 1.9
HF patients? - Adjusted effect: HR = 1.4; 95%CI 1.2 – 1.6
- Heterogeneous effect due to population sizes and prevalence
- OPERA-HF: HR: 3.0; 95% CI: 1.3 to 7.0 (adjusted effect)
Anxiety
- Prevalence: 29%
- No significant effect
Continued on next page
147
Chapter 7. General discussion
Table 7.1 – Continued from previous page
Research question Findings
Which other psychosocial Composite endpoint: readmission or mortality
factors affect adverse OPERA-HF: 70% event rate at 1 year follow up
outcomes in HF? Depression
What is their association - First event: HR = 1.7; 95%CI 1.2 – 2.4
with first and recurrent - Recurrent events: HR = 1.8; 95%CI 1.4 – 2.2
events? Anxiety
- First event: HR = 1.7; 95%CI 1.2 – 2.3
- Recurrent events: HR = 1.4; 95%CI 1.1 – 1.7
Cognitive impairment
- First event: HR = 1.4; 95%CI 0.9 – 2.3
- Recurrent events: HR = 1.4; 95%CI 1.1 – 1.9
Living alone
- First event: HR = 1.0; 95%CI 0.9 – 1.3
- Recurrent events: HR = 1.2; 95%CI 1.1 – 1.4
Frailty (trouble bathing or dressing)
- First event: HR = 1.3; 95%CI 1.1 – 1.7
- Recurrent events: HR = 1.2; 95%CI 1.0 – 1.4
Frailty (timed get-up-and-go test)
- First event: HR = 1.02; 95%CI 1.01 – 1.03
- Recurrent events: HR = 1.01; 95%CI 1.01 – 1.02
Can we predict early Improved discrimination by adding physical frailty and social
readmission or mortality support to clinical variables
with a model that is Discrimination still modest
transportable to a different - Internal validation on OPERA-HF
geography? (AUC 0.7 – corrected for optimism: 0.67)
Good calibration from EU to US
- External validation on SAPHIRE-HF (AUC 0.7)
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MAIN FINDINGS
Research question 1: What is the impact of depression and anxiety on mortality in
HF patients?
To address the first research question we followed a twofold approach. First, we con-
ducted a systematic review and meta-analysis followed by the use of data from the
OPERA-HF study to validate our findings from the systematic review on this cohort.
In the systematic review, we identified 26 and 6 articles meeting inclusion criteria for
depression and anxiety, respectively. The prevalence of both depression and anxiety
in the identified studies was on average 29%. We found that depression is a signif-
icant and independent predictor of all-cause mortality among HF patients but with
very heterogeneous effects reported across the different studies. For example, the ad-
justed effect of depression on mortality reported by Kato [5] was Hazard Ratio (HR)
= 5.52, while the effect on the same outcome reported by Junger [6] was HR = 1.08.
We performed a random-effect meta-regression to explore possible sources of this het-
erogeneity and we found that significant heterogeneity was associated with the total
study population size and the prevalence of the depression in the study. The effect
of depression was smaller in larger studies, which might reflect publication bias with
small studies more often being published when reporting large effect estimates and
less often published when reporting low effect estimates. Smaller effects were also
observed in studies with higher prevalence of depression. That may relate to the use
of different cut-offs on an underlying, latent, scale for depression. If a more liberal
cut-off was used, those labeled as depressed actually were milder than with a more
strict definition of depression.
The pooled unadjusted effect estimate from the literature for depression was 1.6 (HR
= 1.6; 95%CI 1.3 – 1.9, P < 0.001) similar to the effect when adjusting for confounders
(HR = 1.4; 95%CI 1.2 – 1.6; p < 0.001). On the other hand, there was no significant
effect of anxiety on mortality identified.
In the OPERA study, we confirmed the strong association of depression with increased
risk of mortality. Moderate-to-severe depression was independently associated to all-
cause mortality in the year following discharge after an admission to hospital for HF
when controlling for age, Charlson Comorbidity Index, NYHA class IV, NT-proBNP
and treatment with mineralocorticoid receptor antagonist, beta-blocker and diuretics
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(HR: 3.0; 95% CI: 1.3 to 7.0; P< 0.05).
Research question 2: Which other psychosocial factors affect adverse outcomes in
HF? What is their association with first and recurrent events?
HF studies mostly focus on demographics or clinical risk factors, such as increasing
age, male, the presence of co-morbidities, reduced left ventricular ejection fraction
(LVEF), increasing New York Heart Association class of symptoms and worse serum
markers and ignore psychosocial or other non-clinical factors [7]. However, as we
showed in the first part of the thesis, depression may have a strong impact on the out-
comes. Other previous research has also proved the association of (physical) frailty
with increasing risk of first readmission or mortality in heart failure [8, 9]. In Chap-
ter 4 we confirmed that depression and frailty were some of the non-clinical factors
independently associated with increased risk of unplanned readmissions or mortal-
ity. Also moderate-to-severe anxiety was independently associated with the combined
outcome of readmission or mortality, even though it was not associated with mortality
outcome alone [10].
Most HF studies are focusing on the impact on the first event; readmission or mor-
tality. Most research, in particular, focuses on 30-day readmission as an outcome of
interest because of the payment reform incentives pushed by policy makers / payers
aiming to improve outcomes. However, HF patients are often experiencing recur-
rent hospitalizations reflecting progression of the underlying disease or exacerbations
due to comorbidities and suboptimal self-care and medication. Taking into account
more events will lead to more power and efficiency in estimating potential risk factors.
Therefore, we extended our analysis to study the recurrent events. In the OPERA-HF
study, there was an event rate of 70% of patients being readmitted or dying at 1-year
follow-up. The 779 patients discharged from the hospital till July 2016 had 559 first
events and 1600 recurrent events. Hence, there would have been 1041 events ignored
if looking only into the first events that the patients experienced.
In the recurrent event analysis, psychosocial or other non-clinical variables indepen-
dently associated with increasing risk of recurrent events in the year following dis-
charge after a HF admission to hospital were: presence of frailty, moderate-to-severe
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depression, and moderate-to-severe anxiety, living alone and the presence of cogni-
tive impairment. Those remained significant predictors when adjusting for age, dia-
betes, history of myocardial infarction, chronic obstructive pulmonary disease, urea
and creatinine at discharge. The effect of depression on the outcome was greater in
the recurrent event analysis than in the first event analysis, while the effect of anxiety
was smaller. Living alone and the presence of cognitive impairment were significant
predictors of recurrent events but not of first event alone.
Research question 3: Can we predict early readmission or mortality with a model
that is transportable to a different geography?
HF patients often experience adverse events early after being discharged from the
hospital, with approximately 25% been readmitted within the first 30 days [1]. Read-
missions within 30 days may be caused by worsening of clinical conditions of the
patient but also due to other factors including lacking social support, being physically
frail or having cognitive issues.
Available risk stratification algorithms for 30-day events (unplanned readmission or
mortality) perform poorly [11] and include mostly risk factors reflecting the clinical
profile of the patient. In Chapter 5, we used data from the OPERA-HF study to de-
velop a 30-day composite outcome model, and we explored the added predictive value
of non-clinical predictors to early outcomes: 30-day unplanned readmission or mortal-
ity within 30 days. The model containing clinical variables alone (not in sinus rhythm,
worst symptoms, increasing urea and NT-proBNP at discharge, and higher daily pill
count) and health care utilization (number of prior emergency hospitalizations in 6
month and length of stay) gave an area under the receiver operating characteristic
curve (AUC) of 0.68 [95% CI 0.64 - 0.72]. By including in the model physical frailty and
social support the AUC increased to 0.70 [95% CI 0.66 – 0.74] (p<0.05). In this model,
we achieved an absolute increase in performance of 0.02 when taking into account
non-clinical factors. The discrimination of the model remained modest reflecting the
difficulty in early readmission or mortality prediction due to the diversity in the read-
mission root causes. However, we showed that by including less frequently evaluated
patient characteristics (physical and social frailty), we can increase the discriminative
value of the model. Another advantage is that our model is based on simple and easy
to obtain variables, it can easily be used as part of the routine care practice and results
151
Chapter 7. General discussion
can be easily interpreted by the clinicians.
External validation. Most available risk stratification algorithms are only internally val-
idated [12]. Internal validation is important to prove the reproducibility of the model
on the original population [13]. This step is important but not enough when aiming to
prove the validity of a model beyond the original population. It should be followed by
external validation that proves the transportability of a model to a different ‘plausibly
related’ population [13, 14, 15].
In the last part of this thesis we evaluated the transportability of the OPERA model
to a different geography. The performance of the model was evaluated by discrimi-
nation and calibration. We used data from the SAPHIRE study, conducted in US, to
externally validate the model. In SAPHIRE study, we collected similar data to the
OPERA-HF. The external validation of the OPERA model was performed on 513 HF
patients enrolled in the SAPHIRE study. Our results showed a good calibration and
discrimination similar to the original. This means that the model can overcome any
difference between the populations of two locations. It can be used in the new popu-
lation to discriminate patients at risk of an early event with a performance equal to the
one from the original derivation setting without any adjustment to the original model.
Early event prediction remains challenging, however, our findings suggest that non-
clinical factors may improve the predictions. Further evidence towards this direction
has been provided by another recent study demonstrating that causes of potentially
preventable readmissions are mostly human-related caused by coordination and com-
munication failures [16]. Furthermore, the generalizability of our model to a different
geography indicates that the model designed for one setting can be used for another
setting, as well.
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METHODOLOGICAL CONSIDERATIONS
Study design
It is widely reported in literature that early outcomes and especially readmissions are
generally hard to predict, due to the heterogeneity of the population characteristics,
the reasons that might be causing a readmission, the short prediction window and
the rare frequency of these events [17, 18, 19]. In the OPERA-HF study, we set up
an intentionally broad protocol to explore different potential predictors. Our analysis
showed that by taking into account frailty or lack of social support we can improve the
discrimination for 30-day emergency readmission or mortality, while more psychoso-
cial factors affect longer term outcomes. However, the discrimination of early events
remains modest recommending further research on other important non-clinical pre-
dictors not yet identified. For instance, a recent study by van Galen et al. [20] reported
that the patient reporting not feeling ready for discharge at index admission was sig-
nificantly associated with the early readmission outcome.
Patient data
One limitation of the OPERA-HF study was that 20% of the patients had missing data
for one or more of the predictors included in the model. The broad protocol requiring
intense data collection, patient burden, collecting data for which diagnostic ground
exists may be some or the reasons explaining the high missing data rates for some
of the parameters. On the other hand, the SAPHIRE-HF/COPD study protocol was
limited to the most important factors identified from the OPERA-HF study or other
clinically significant factors indicated by domain experts. The difference in the size of
the protocol may be one of the reasons explaining the smaller number of missing data
in the SAPHIRE-HF/COPD study. In both studies, to overcome the missing data issue
we used the multiple imputation technique [21].
With respect to follow-up data, we anticipated only a limited amount of outcome data
missing in both studies. In both cases, we recruited study participants living in the
local areas. However, there is still a possibility of missed events due to seeking care
outside of the local areas that may result in an underestimation of readmission rates.
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Additional assessment
In both studies, patients were asked to complete additional physical exams or psy-
chosocial assessments via questionnaires in order to obtain a more holistic assessment
of their status. These additional assessments are not part of the routine care provided
to the patients.
There are different methods available that can provide assessments of depression, anx-
iety, social support, frailty or other characteristics of the patients. A limitation of some
of the assessment methods used in our studies, for instance the HADS questionnaire
for depression and anxiety [22], is that they have been developed primarily for re-
search and have not been extensively tested in routine practice for patients with heart
failure.
Another potential limitation of these assessments is that they may be subjective de-
pending on the patient’s physical or mental condition at the time of administration.
They may rely on participant’s perception of their own health and their ability to recall
past experiences and events. Next to that, most of these assessments were performed
once during patient’s hospitalization. Hence, we may have missed significant changes
of patient’s status during or after hospitalization.
154
Chapter 7. General discussion
IMPLICATIONS AND FUTURE RESEARCH
The OPERA model takes into account frailty and social support next to healthcare
utilization and clinical predictors to calculate a risk score of early adverse events for
the patients. This risk score can be used by the discharge teams as part of the routine
practice to identify patients at different risk levels. The model does not aim to replace
but to assist clinicians or discharge teams to identify optimal care pathways for their
patients. Some examples of interventions linked to different risk levels are given in
Table 7.2. Further research is recommended to identify the optimal thresholds for the
risk levels.
Patients with the highest risk scores are typically very complex, end stage heart failure
patients who would benefit mainly from interventions such as palliative care. High
risk patients usually require intense care and support by specialist, primary care and
informal caregivers. One possible solution to support high risk patients effectively in
their own home is telehealth [23]. HF patients in the medium risk levels, on the other
hand could benefit by less intense interventions such as structured m-health support
or lower intensity telehealth solutions [24]. HF patients with the lowest risk scores are
usually well self-managed and they might only need clinical and social support with
respect to health coaching and lifestyle management in order to maintain their risks
low.
Often a multidisciplinary management approach is needed in order to identify the pa-
tients’ needs and the interventions that would benefit them the most. The knowledge
on the impact of specific factors on the outcomes can improve discharge management
and explore interventions tailored to patient needs that may improve the outcomes.
Our study recommends that non-clinical or non-disease specific factors should not be
neglected when assessing a patient’s status and needs. A holistic assessment of the
patients’ status with them also engaged in the process of deciding what is best for
them (shared decision making) may help to optimize the care provided to the patients
and identify avoidable hospitalizations. Depression or frailty are some of the factors
that appear to be strongly related to the outcomes and it could be beneficial to include
their assessment as part of the routine care provided to HF patients. The presence of
certain non-disease specific factors should be taken into account while defining inter-
disciplinary treatment programs tailored to individual patient needs. The multidisci-
plinary management team may consist of HF specialist, physiotherapist, geriatrician,
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rehabilitation physician, nurse and dietician depending on each patient’s needs.
Cognitive Behavioral Therapy (CBT) or physical exercise are some of the interventions
with positive effect on outcomes for patients with depression or frailty [24, 25, 26, 27,
28]. On the contrary, there is no evidence that antidepressants could positively affect
the outcomes in patients with HF [29]. Multidisciplinary collaborative management
to identify individual patients’ needs, physical exercise or support groups are some of
the interventions with positive impact on outcomes when the patient is lacking social
support [28, 30]. Randomized controlled trials are recommended to evaluate the im-
pact of these interventions on HF patients also in combination with other interventions
such as telehealth.
In this thesis, we have reported a strong impact of psychosocial factors and frailty on
several adverse outcomes of HF patients. There is evidence that many of these factors
are affecting other groups of patients, as well. For example, frailty is increasingly rec-
ognized as an important factor in managing patients with long term conditions [31].
Major depression [32, 33] and cognitive impairment [34] have also been associated
with high risk of death in older populations. Next to them, lack of social support is of-
ten associated with adverse follow-up outcomes in hospitalized patients [35]. Further
research and evaluation of our findings on other patient groups is recommended.
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TABLE 7.2: HF patient characteristics and managements in different risk levels
Risk level Patient profile Possible interventions at discharge
Very high risk Terminal ill or very severe/ Nursing home, palliative care
complex patients
(e.g. transplantation or having
other dominant (chronic) disease)
High risk - At risk of (recurrent) hospital Intense care
complex emergency admissions (e.g. high intensity telemonitoring),
needs or attendances to hospital. community specialist nurse support,
Unstable condition. multidisciplinary management,
Have difficulty following social care
medication or treatment regimes.
Medium risk - Lower chance to have Lower intensity telemonitoring,
less complex unplanned readmissions multidiciplinary management,
needs within the next year, Community specialist nurse support,
chance of deterioration. social care, proactive care planning
Low risks Well self-managed or early stage/ GP/practice nurse follow up in CDM
low severity HF patients. clinics, primary care management,
Able to maintain a health coaching and lifestyle
good health management. management, community activities
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CONCLUSIONS
The research in this thesis aims to highlight new risk factors for HF adverse events
and contribute in the improvement of predictive models for HF patients. We showed
the strong effect of several psychosocial or non-disease specific factor with adverse
outcomes in HF patients. Depression is strongly associated with increasing risk of
recurrent hospitalizations or mortality in the year following discharge after an admis-
sion to hospital for HF. Other factors also related to increasing risk of recurrent events
are the presence of frailty, moderate-to-severe anxiety, living alone and the presence
of cognitive impairment. When looking into short-term outcomes, frailty and lack of
social support both improved the discriminative power of a model predicting 30-day
readmission or mortality.
These findings may enable researchers and health care providers to identify patients
at risk of adverse events that are potentially avoidable and to adjust their decisions
about patients’ discharge to optimize the care provided them. Currently, the patient’s
status and post-discharge services are assessed by the professionals at the cardiology
ward (cardiologists, nurses and/or the care managers) in an ad-hoc way, which may
vary between professionals and institutions based on experience and knowledge. Our
tool enables them to assess the patient’s condition in a more systematic way from a
holistic perspective, to stratify the patients in different risk levels and to recommend a
multidisciplinary management or other interventions where needed.
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RECOMMENDATIONS
The findings of our research allow for the following recommendations to health care
professionals and researchers.
Recommendations for clinical practice
• Holistic assessment of the patient as part of routine care by a multidisciplinary
team might be beneficial. The team may consist of HF specialist, physiotherapist,
geriatrician, rehabilitation physician, nurse and dietician depending on each pa-
tient’s needs.
• Do not neglect psychosocial aspects or frailty when assessing patients’ condition.
• Use the OPERA model as part of routine care to identify patients at high risk of
early events.
Recommendations for research
• Explore further non-clinical factors that may improve the prediction of outcomes
for HF patients.
• Investigate the added value of frailty, social support and depression in predictive
models for long-term outcomes.
• Validate our findings beyond HF patients on COPD or other chronic disease pa-
tients.
• Use the knowledge on impact of non-clinical factors to improve discharge man-
agement by involving a multidisciplinary team and next to the HF related inter-
ventions take into account interventions such as CBT, multidisciplinary manage-
ment, physical exercise, counseling and education tailored to individual patient’s
needs.
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[8] J. Lupón, B. González, S. Santaeugenia, S. Altimir, A. Urrutia, D. Más, C. Dı́ez, T. Pascual, L. Cano,
and V. Valle, “Prognostic implication of frailty and depressive symptoms in an outpatient popula-
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The main aim of this thesis is to explore risk factors associated to an increased risk of
adverse outcomes for heart failure (HF) patients and improve the early re-admission
or mortality prediction in HF.
The first part of the thesis includes the general introduction. HF is a progressive dis-
ease and a major cause of morbidity and mortality worldwide. HF disease manage-
ment can be difficult because besides medical treatment it requires significant lifestyle
changes such as exercise, restricted fluid and salt intake and medication adherence.
Therefore, despite the improvements in disease management, HF is often associated
with poor quality of life and multiple hospital admissions. A portion of re-admissions
can be prevented by predicting if they will occur and tailoring disease management
interventions accordingly. Hence, identifying risk factors affecting adverse events in
HF patients is important for patients and healthcare providers, because they may lead
to new methods to manage patients and optimize services.
We designed the OPERA-HF study in the UK, to explore a wide range of variables
as potential risk factors. In addition to demographic, clinical, imaging and laboratory
variables, we explored non-disease specific and non-clinical variables that could act
as predictors for re-admission or mortality in patients with HF following an admis-
sion for HF. We aimed to identify variables that could improve the discrimination for
re-admission or mortality prediction. In order to validate our findings and their gen-
eralizability beyond the development cohort we utilized the SAPHIRE study, a patient
cohort from the US.
In the second part of the thesis, we study the impact of depression and other psy-
chosocial factors on adverse outcomes. We conducted a systematic review and meta-
analysis where we found that the prevalence of both depression and anxiety in the
identified studies was on average 29%. We found that depression is a significant and
165
independent predictor of all-cause mortality among HF patients but with very hetero-
geneous effects reported across the different studies. The heterogeneity was associated
with the total study population size and the prevalence of depression in the study. On
the other hand, there was no significant effect of anxiety on mortality identified.
Subsequently we confirmed the strong association of depression with increased risk of
mortality, in the OPERA-HF study. Moderate-to-severe depression was independently
associated to all-cause mortality in the year following discharge after an admission to
hospital for HF when controlling for age, Charlson comorbidity index, NYHA class IV,
NT-proBNP and treatment with mineralocorticoid receptor antagonist, beta-blocker
and diuretics. In the OPERA-HF study, moderate-to-severe depression was also signif-
icantly associated with recurrent events: unplanned readmission or mortality. Other
psychosocial or non-clinical variables independently associated with increasing risk of
recurrent events in the year following discharge after a HF hospital admission were:
presence of frailty, moderate-to-severe anxiety, living alone and the presence of cogni-
tive impairment.
In the third part of the thesis, we used data from the OPERA-HF study to develop
a 30-day composite outcome model and we explored the added predictive value of
non-clinical predictors to early outcomes: 30-day unplanned readmission or mortality
within 30 days. A model containing clinical variables alone had an area under the
receiver-operating characteristic curve (AUC) of 0.68. By including physical frailty
and social support in the model the AUC increased to 0.70. The discrimination of
the model remained modest reflecting the difficulty in early readmission or mortality
prediction due to the diversity in the readmission root causes.
We then used data from the SAPHIRE study to externally validate the model. Our re-
sults showed a good calibration and discrimination similar to the original. This means
that the model can overcome any difference between the populations of two locations.
Early event prediction remains challenging, however, our findings suggest that non-
clinical factors may improve the predictions and they should not be neglected when
assessing a patient’s status and needs.
In the last part of the thesis, the general discussion, we summarize the findings, we
provide answers to the main research questions addressed in this thesis and present
recommendations for future research.
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Nederlandse samenvatting
Het hoofddoel van dit proefschrift is om risicofactoren te onderzoeken die geasso-
cieerd zijn met een verhoogd risico op ongunstige uitkomsten voor patiënten met hart-
falen en om de voorspelling van vroegtijdige heropname of sterfte van patiënten met
hartfalen te verbeteren.
Het eerste deel van het proefschrift omvat de algemene inleiding. Hartfalen is een pro-
gressieve ziekte en een belangrijke oorzaak van morbiditeit en mortaliteit wereldwijd.
De zorg van hartfalen is uitdagend omdat aanzienlijke veranderingen in leefstijl op
het gebied van lichaamsbeweging, beperkte vocht- en zoutinname en therapietrouw
noodzakelijk zijn voor een effectieve behandeling.
Ondanks de verbeteringen in de zorg, wordt hartfalen daarom vaak geassocieerd met
een slechte kwaliteit van leven en meerdere ziekenhuisopnames. Een deel van de
heropnames kan worden voorkomen door nauwkeurige voorspelling van deze op-
names te doen en daarop het behandelplan met zorginterventies aan te passen. Het
identificeren van risicofactoren gerelateerd aan heropnames en sterfte van patiënten
met hartfalen is daarom belangrijk voor patiënten en zorgverleners, omdat het kan
leiden tot nieuwe methoden voor betere zorg met betere interventies.
We hebben de OPERA-HF studie in het Verenigd Koninkrijk opgezet om een breed
scala aan variabelen te verkennen als mogelijke risicofactoren. Naast demografische,
klinische, beeldvormende en laboratoriumvariabelen, hebben we niet- ziektespeci-
fieke en niet-klinische variabelen onderzocht en hun waarde geëvalueerd als voor-
spellers voor heropname of sterfte bij patiënten met hartfalen na een opname voor
hartfalen. We wilden een klein aantal variabelen identificeren dat een zo goed mo-
gelijk onderscheid zou geven voor de voorspelling van heropname of sterfte. Om onze
bevindingen en hun generaliseerbaarheid buiten het ontwikkelingscohort te valid-
eren, zijn de resultaten getoetst met de SAPHIRE studie, een patiëntencohort uit de
Verenigde Staten.
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In het tweede deel van het proefschrift bestuderen we de invloed van depressie en
andere psychosociale factoren op ongunstige uitkomsten bij hartfalen. We hebben
een systematisch literatuuronderzoek en meta-analyse uitgevoerd waarbij naar voren
kwam dat de prevalentie van depressie en angst in de geı̈dentificeerde onderzoeken bij
patiënten met hartfalen gemiddeld 29% was. Depressie als variabele bleek een signif-
icante en onafhankelijke voorspeller van algemene sterfte bij patiënten met hartfalen,
maar met zeer uiteenlopende effectgroottes die in de verschillende onderzoeken zijn
gemeld. De heterogeniteit was geassocieerd met de totale omvang van de onderzoek-
spopulatie en de prevalentie van depressie in het onderzoek. Aan de andere kant is er
geen significant effect gevonden voor de relatie tussen angst en algemene sterfte.
Op basis van de analyse van de gegevens van de OPERA-HF studie is er een sterke
associatie van depressie met verhoogd risico op sterfte gevonden. Matige tot ernstige
depressie was onafhankelijk geassocieerd met algemene sterfte in het jaar na ontslag
van een aan hartfalen gerelateerde opname in het ziekenhuis, waarbij gecorrigeerd is
voor leeftijd, Charlson Comorbidity Index, NYHA klasse IV, NT-proBNP en behandel-
ing met aldosteron-antagonist, bètablokker en diuretica.
In de OPERA-HF studie was matige tot ernstige depressie ook significant geassocieerd
met herhaaldelijke heropnames of sterfte. Andere psychosociale of niet-klinische vari-
abelen die onafhankelijk geassocieerd bleken met een verhoogd risico op recidive
in het jaar na ontslag na een opname voor hartfalen in het ziekenhuis waren: aan-
wezigheid van ouderdomszwakte, matige tot ernstige angst, alleen leven en de aan-
wezigheid van cognitieve aandoeningen.
In het derde deel van het proefschrift zijn de gegevens uit de OPERA-HF studie ge-
bruikt om een model te genereren gericht op het voorspellen van heropname of sterfte
binnen 30 dagen na ontslag. Daarbij onderzochten we de toegevoegde voorspellende
waarde van niet-klinische voorspellers voor de afzonderlijke uitkomsten. Een model
met alleen klinische variabelen had een C-statistiek (AUC; oppervlakte onder de re-
ceiver operating characteristic curve) van 0,68. Door in het model ouderdomszwakte
en sociale ondersteuning op te nemen, steeg de C-statistiek tot 0,70. Het onderschei-
dend vermogen van het model bleef bescheiden en illustreert de mate van complexiteit
van het voorspellen van vroegtijdige heropname of sterfte vanwege de verscheiden-
heid aan mogelijke oorzaken.
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Vervolgens hebben we gegevens uit de SAPHIRE-studie gebruikt om het voorspel-
lend model extern te valideren in een ander cohort. Onze resultaten toonden een
goede kalibratie en onderscheidend vermogen aan voor het model in dit nieuwe co-
hort, vergelijkbaar met de prestatie in het oorspronkelijke cohort. Dit betekent dat het
model de mogelijke verschillen tussen de twee cohorten van de twee locaties kan com-
penseren. Het voorspellen van gebeurtenissen als vroegtijdige heropname en sterfte
bij patiënten met hartfalen blijft een uitdaging, maar onze bevindingen geven aan dat
niet-klinische factoren de voorspellingen kunnen verbeteren en overwogen zouden
moeten worden bij het beoordelen van de toestand en behoeften van een patiënt.
In het laatste deel van het proefschrift, de algemene discussie, vatten we de bevin-
dingen samen, geven we antwoorden op de belangrijkste onderzoeksvragen in dit
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